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Abstract 
 
Curcumin (1) is a secondary metabolite isolated from the turmeric of Curcuma 
longa. Many molecular targets have been identified for this compound, hence 
corroborating its diverse biological activities. Particularly, curcumin (1) has been shown to 
act as multidrug resistance (MDR) modulator in various cancer cell models by 
downregulating the MDR1 gene expression and, therefore, decreasing the cellular levels 
of P-glycoprotein (P-gp). Thus, the structure of curcumin (1) may represent an important 
basis for development of effective therapeutic agents to overcome the problem of MDR in 
cancer. However, curcumin (1) has low chemical and photostability, which severely limits 
its application. 
In order to improve stability and P-gp inhibitory effects we proposed to synthesize 
three stable curcumin derivatives as building blocks and several curcumin derivatives 
derived from the synthesized building blocks with enhanced P-gp inhibitory activity. 
Several synthetic strategies were used to successfully synthesize the target compounds: 
Claisen-Schmidt condensation reactions, SN2 reactions, Mannich reaction, and click 
chemistry. Two building blocks (117 and 33) were successfully synthesized and, on the 
basis of our current state of knowledge seven of the ten derivatives (117, 33, 119, 120, 
121, 122, 123, 124, 125, and 126) synthesized are being described for the first time. 
The structure elucidation of the synthesized derivatives (117, 33, 119, 120, 121, 
122, 123, 124, 125, and 126) was established on the basis of IR, UV-Vis, MS, HRMS, and 
NMR techniques. 
Stability and photostability studies were conducted by comparing curcumin (1) with 
the enone (117) and dienone (33) building blocks. Different assays were performed in 
order to evaluate the compounds stability subjected to several pH buffers, biological 
medium buffer, temperatures and storage times. 
The main focus of the biological tests was to evaluate the tumor cell growth 
inhibitory activity in two lung cancer cell lines (resistant and non-resistant) and to 
determine P-gp inhibitory activity in a P-gp overexpressing leukemia cell line. Five of the 
synthesized compounds (117, 119, 120, 121, e 125) and curcumin (1) were tested 
according to the procedure for the sulforhodamine B (SRB) assay (cytotoxicity evaluation), 
and the rhodamine 123 efflux assay (P-gp inhibition assay). Preliminary results obtained 
as a collaboration are presented. 
 
Keywords: Curcumin, Multidrug resistance, Curcumin derivatives, P-glycoprotein 
inhibition. 
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Resumo 
 
A curcumina (1) é um metabolito secundário isolado do açafrão-da-índia, da planta 
Curcuma longa. Muitos alvos moleculares foram identificados para este composto, 
corroborando assim com as suas diversas atividades biológicas. Particularmente, a 
curcumina (1) mostrou ser um modulador da resistência múltipla a fármacos em vários 
modelos de células cancerígenas através da diminuição da expressão do gene MDR1 e, 
consequentemente, diminuição dos níveis celulares de glicoproteína-P (P-gp). Assim 
sendo, a estrutura da curcumina (1) pode representar uma base importante para o 
desenvolvimento de agentes terapêuticos eficazes para superar o problema da 
resistência múltipla a fármacos no cancro. Contudo, a curcumina (1) têm baixa 
estabilidade química e fotoquímica, o que limita seriamente a sua utilização. 
A fim de melhorar a estabilidade e efeito inibidor da P-gp propusemos a síntese de 
três derivados estáveis da curcumina como blocos construtores e de vários derivados da 
curcumina produzidos a partir dos blocos construtores sintetizados, de forma a possuírem 
maior actividade inibidora da P-gp. Várias estratégias sintéticas foram utlizadas para 
sintetizar com sucesso os compostos desejados: reacções de condensação de Claisen-
Schmidt, reacções SN2, reacção de Mannich, e química “click”. Dois blocos construtores 
(117 e 33) foram sintetizados com sucesso e, com base no nosso conhecimento actual, 
sete dos dez compostos sintetizados (117, 33, 119, 120, 121, 122, 123, 124, 125, e 126) 
estão a ser descritos pela primeira vez. 
A elucidação estrutural dos derivados sintetizados (117, 33, 119, 120, 121, 122, 
123, 124, 125, e 126) foi estabelecida com base em IV, UV-Vis, MS, HRMS e técnicas de 
RMN. 
Os estudos de estabilidade e fotoestabilidade foram realizados comparando a 
curcumina (1) com os blocos construtores sintetizados, enona (117) e dienona (33). 
Diferentes ensaios foram realizados de forma a avaliar a estabilidade dos composto 
quando sujeitos a tampões com diferentes pHs, o meio biológico das células, diferentes 
temperaturas e tempos de armazenamento. 
O principal objectivo dos ensaios biológicos era avaliar a atividade inibidora do 
crescimento de células tumorais em duas linhas de cancro no pulmão (resistente e não-
resistente) e determinar a actividade inibidora da P-gp numa linha celular leucémica que 
superexpressa P-gp. Cinco dos compostos sintetizados (117, 119, 120, 121, e 125) e a 
curcumina (1) foram testados de acordo com o procedimento para o ensaio da 
sulforodamina B (SRB) (avaliação da citotoxicidade), e para o ensaio de efluxo da 
xi 
 
rodamina 123 (avaliação da inibição da P-gp). Os resultados preliminares obtidos como 
colaboração são apresentados. 
 
Palavras-Chave: Curcumina, Resistência múltipla a fármacos, Derivados da 
curcumina, Inibição da glicoproteína-P. 
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OUTLINE OF THE THESIS 
 
The present dissertation consists of five chapters: 
 
Chapter I: INTRODUCTION  
Chapter I provide the research background of the work done with special emphasis 
on curcumin and its biological activities, multidrug resistance in cancer and some of the 
curcumin derivatives that have already been described as tumor cell growth inhibitors 
and/or multidrug resistance modulators. A more intensive study on curcumin derivatives 
and respective biological activities was submitted as a review manuscript.. 
 
Chapter II: RESULTS AND DISCUSSION 
This chapter is divided into three subchapters emphasizing the results obtained 
concerning the synthesis and structure elucidation, the stability and photostability studies, 
and the biological activity of the synthesized derivatives. Herein, some structure-activity 
relationships (SAR) considerations are presented. Biological activity studies of the 
synthesized compounds were performed by Vanessa Rodrigues under supervision pf 
Professor Helena Vasconcelos at IPATIMUP.. 
 
Chapter III: MATERIAL AND METHODS  
In this chapter the synthetic and purification methodologies are described for the 
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Chapter IV: CONCLUSIONS 
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proposed aims. 
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1. Curcumin 
 
1.1. Curcumin, general features 
 
Curcumin (1, Figure 1) is a secondary metabolite of the well-known Indian spice 
turmeric, derived from the rhizomes of Curcuma longa, of the Zingiberaceae family 1. 
Curcumin (1) has been used in Ayurvedic medicine for thousands of years, as a treatment 
for inflammatory diseases and wounds 2-3. Curcumin (1) is a polyphenol, and it is the main 
component of the yellow-pigmented fraction of turmeric 4. Besides curcumin (1), this 
fraction of turmeric also contains demethoxycurcumin (DMC, 2) and 
bisdemethoxycurcumin (BDMC, 3), collectively called curcuminoids (Figure 1) 5. Hence, 
DMC (2) and BDMC (3) are naturally-occurring analogues of curcumin (1). Curcuminoids 
represent 3-5% of turmeric. Commercially available extract contains different percentages 
of these compounds: 77% curcumin (1), 17% DMC (2), and 3% BDMC (3) 5. Traditionally, 
curcumin (1) has been used as a coloring agent in foods, medicine, and cosmetics. As a 
spice, it is used to provide curry with its characteristic yellow color, flavor, and aroma 4. 
A captivating feature of curcumin (1), and one of the main reasons why it has been 
extensively studied and is still used in traditional medicine, is the extremely good safety 
profile. To date, no studies in either animals or humans have discovered toxicity 
associated with the use of curcumin (1), even when tested at high doses 4. Indeed, the 
U.S. Food and Drug Administration has approved curcumin (1) as a “generally regarded 
as safe” compound 6. 
 
 
Figure 1 - Curcuminoids of the yellow-pigmented fraction of turmeric: curcumin (1), DMC (2), 
and BDMC (3). 
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Curcumin (1) or (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene,3,5-
dione, is an yellow-orange powder with a melting point of approximately 183oC. This 
compound exhibits keto-enol tautomerism; however, once in solution it exists mainly in its 
enolic form (Figure 2) 4-5. The enolic form of curcumin (1) has three ionizable groups: the 
enolic group and the two phenolic groups. The pKa value for this compound is 8.54 1. 
 
 
Figure 2 - The keto-enol tautomerism of curcumin (1). 
 
Poor bioavailability of curcumin (1) can be explained by its poor water solubility and 
extensive metabolism. Curcumin (1) could only be orally effective as a drug if it could be 
absorbed by the gut and enter the bloodstream; thus solubility would be essential in this 
process. However, curcumin (1) is excreted from the gut, and if patients were to be 
subjected to curcumin (1) as an oral therapy, they would have to ingest 12 to 20 g of 
curcumin (1). Such doses are however too high, since more than 10 g of curcumin (1) 
leaves an intolerable aftertaste in the mouth 7. Nevertheless, in spite of the bioavailability 
problems of curcumin (1), this compound has recognized biological and therapeutic 
properties. 
 
 
1.2. Biological activities of curcumin 
 
For thousands of years curcumin (1) has been used as a therapeutic agent 
throughout the Orient. The impressive healing properties and safety of curcumin (1) 
motivated research groups all over the world to study this natural product. Curcumin (1) 
was shown to have many biological activities, such as antioxidant, cardio and 
neuroprotective, antidiabetic, antimicrobial, antimalarial, anti-human immunodeficiency 
virus (HIV), thrombosuppressive, antitumor and chemopreventive activities 4-5. Curcumin 
(1) even seems to control numerous cancer treatment-related symptoms, such as 
depression 8. 
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Over the past few years, many review articles have been published on the subject of 
curcumin (1) biological activities 4-5, 8-12. Several studies suggest that curcumin (1) has a 
diverse range of molecular targets, which supports the idea that this molecule influences a 
great variety of biochemical and molecular cascades. Figure 3 displays the molecular 
targets of curcumin (1) described until now 4, 8, 13. 
In response to the growing interest in curcumin (1) and its biological activities, 
several clinical trials have addressed the safety, pharmacokinetics and efficacy in 
humans. These trials have also studied the biological activities of curcumin (1) that are of 
greatest interest and that have showed best results in in vitro and pre-clinical assays. 
Currently, about 104 trials are either ongoing or have been completed, worldwide 14. 
 
 
1.3. Curcuminoids 
 
Curcuminoids exhibited antioxidant activity both in vitro and in vivo models, even 
though to different extents. The curcuminoids 1-3 inhibited lipid peroxidation caused by 
Fenton reagent, metals, H2O2 and 2,2’-azo-bis(2-amidinopropane) (AAPH), in several in 
vitro models 15-17. Curcuminoids 1-3 also revealed other antioxidant activities, such as 
scavenging of reactive oxygen species like superoxide anions and hydrogen peroxide, 
and inhibition of low density lipoproteins oxidation 18-19. 
In an in vitro assay, the individual components of the curcuminoids (compounds 1-3) 
have shown acetylcholinesterase (AChE) inhibitory activity 20. The most potent was BDMC 
(3), followed by DMC (2) and curcumin (1). Probably the methoxyl group, present in 
curcumin (1) and DMC (2), reduces the AChE inhibitory activity. The curcuminoids mixture 
was less effective in vitro than BDMC (3). However, in an ex vivo assay, the curcuminoids 
mixture presented better results, which could indicate that curcuminoids as a mixture 
might be better penetrating agents of the blood brain barrier, or that they can have 
synergistic interactions between them. Curcumin (1) by itself has shown negligible effect 
in the ex vivo assay, perhaps due to poor absorption and low penetration into the brain 20.
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Figure 3 - Molecular targets of curcumin (1). Transcription factors include: signal transducers and activator of transcription-1 (STAT-1), STAT-3, STAT-
4, STAT-5, β-catenin, nuclear factor-kappa B (NF-κB), Notch-1, nuclear factor 2-related factor (Nrf-2), cAMP-response element-binding protein (CREB-BP),
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activating transcription factor-3 (ATF-3), activation protein-1 (AP-1), p53, electrophile response 
element (ERE), specificity protein-1 (Sp1), Wilm’s tumor gene (WT-1), early growth response gene-
1 (EGR-1), C/EBP homologous protein (CHDP), hypoxia inducible fator-1 (HIF-1) and peroxisome 
proliferator-activated receptor-gamma (PPAR-γ). Inflammatory mediators include:  tumor necrosis 
factor alpha (TNF-α), interleukin-1β (IL-1β), IL-2, IL,5, IL-6, IL-8, IL-12, IL-18, macrophage 
inflammatory protein (MaIP), prostate specific antigen (PSA), monocyte chemoattractant protein 
(MCP), interferon-γ, C-reactive protein (CRP) and  migration inhibition protein (MIP).  Enzymes 
include: ATPase, DNA polymerase I (DNA pol I), inducible nitric oxide synthase (iNOS), 
gluthathione-S-transferase (GST), lipoxygenase (LOX), farnesyl protein transferase (FPT), 
arylamine N-acetyltransferase-1 (NAT-1), telomerase, hemeoxygenase-1 (HO-1), glutathione 
reductase (GR), src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2), 
NAD(P)H:quinone oxiredutase (NQO-1), phospholipase D (PLD), aminopeptidase N (CD13), 
inosine monophosphate dehydrogenase (IMPDH), Ca
2+
 dependent ATPase (Ca
2+
 dep. ATPase), 
glutamyl cysteine ligase (GCL), cyclooxygenase-2 (COX-2), ornithine decarboxylase (ODC), 
desnaturase, monoamine oxidase (MAO), GTPase (microtubule assembly) (GTPase MT 
assembly), ubiquitin isopeptidases (DUBs), beta-site APP-cleaving enzyme-1 (BACE1), aldose 
reductase (aldose red), acetylcholinesterase (AChE), thioredoxinreductase 1 (TXNRD1), 17β-
hydroxysteroid dehydrogenase type 3 (17β-HSD3), glutathione-peroxidase (GPx), tissue inhibitor of 
metalloproteinase-3 (TIMP-3) and DNA topoisomerase II. Kinase include: mitogen-activated protein 
kinase (MAPK), protein kinase A (PKA), protein kinase B (PKB), protein kinase C (PKC), epidermal 
growth factor receptor-kinase (EGFR-K), phosphatidylinositol 3-kinase/Akt (PI3K-Akt), pp60c-src 
tyrosine kinase (pp60c-scr), autophosphorylation-activated protein kinase (CAK), Janus kinase 
(JAK), protein tyrosine kinase (PTK), IL-1 receptor-associated kinase (IL-1 RAK), IκB kinase (IκB), 
focal adhesion kinase (FAK), c-jun N-terminal kinase (JNK), protamine kinase (cPK), 
phosphorylase kinase (PhK), Ca
2+
-dependent protein kinase (CDPK) and extracellular receptor 
kinase (ERK). Growth factors include: transforming growth factor-β1 (TGF-β1), platelet derived 
growth factor (PDGF), connective tissue growth factor (CTGF), epidermal growth factor (EGF), 
vascular endothelial growth factor (VEGF), nerve growth factor (NGF), human epidermal growth 
factor receptor-2 (HER-2), tissue factor (TF), fibroblast growth factor (FGF), and hepatocyte growth 
factor (HGF). Receptors include: histamine 2-receptor (H2-R), aryl hydrocarbon receptor (Arh-R), 
endothelial protein C-receptor (EPC-R), LDL-receptor (LDL-R), EGF-receptor (EGF-R), androgen 
receptor (AR), integrin receptor (IR), interleukine 8-receptor (IL-8-R), Fas receptor (Fas-R), 
estrogen receptor-alpha (ER-α),  transferrin receptor 1 (TfR), inositol 1,4,5-triphosphate receptor 
(InsP3-R) and death receptor-5 (DR-5). Adhesion molecules include: endothelial leukocyte 
adhesion molecule-1 (ELAM-1) and intracellular adhesion molecule-1 (ICAM-1). Anti-apoptotic 
proteins include: X-linked inhibitor of apoptosis protein (XIAP), cellular FLICE-like inhibitor protein 
(C-FLIP), B-cell lymphoma protein-2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), and inhibitory 
apoptosis protein-1 (IAP-1). Cell-cyle regulatory proteins include: cyclin D1, cyclin E, c-Myc and 
p21. Drug resistance proteins include: P-glycoprotein (P-gp) and multi-drug resistance protein-2 
(MDR2). Chemokines and chemokine receptor include: chemokine ligand 1 (CCL1), chemokine 
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ligand 2 CCL2 and chemokine (C-X-C motif) receptor 4 (CXCR4). Invasion and angiogenesis 
biomarkers include: vascular cell adhesion molecule-1 (VCAM-1), matrix metalloproteinase-9 
(MMP-9), and urokinase-type plasminogen activator (uPA). Others include: DNA fragmentation 
factor 40kD subunit (DFFB), prion fibril, ferritin H and L, heat-shock protein 70 (HSP-70), fibrinogen 
and iron regulatory protein (IRP). 
 
 
The curcuminoids DMC (2) and BDMC (3) also revealed cardioprotective, anti-
inflammatory, antitumor, antidiabetic, nematocidal and neuroprotective activities 5. Among 
curcuminoids 1-3, BDMC (3) exhibited the highest tumor cell growth inhibitory effect 
against the ovarian cancer cells, OVCAR-3 21. BDMC (3) was also found to be the most 
effective in increasing the life span of swiss albino mice bearing Ehrlich ascites 22. DMC 
(2) and BDMC (3), although not as effective as curcumin (1), increased the KB-V1 (P-gp 
overexpressing) cellular sensitivity to vinblastine, blocked the efflux of fluorescent P-gp 
substrates and inhibited verapamil-stimulated adenosine triphosphatase (ATPase) activity 
in KB-V1 cells 23. In a different study, DMC (2) inhibited P-gp-mediated ATP hydrolysis 
with lower concentration than curcumin (1) and BDMC (3) 24. 
 
 
1.4. Curcumin metabolites 
 
As it was previously mentioned, curcumin (1) has to be absorbed by the gut and 
enter the bloodstream in order to be orally-effective. However, when curcumin (1) is orally 
administrated it undergoes metabolic O-conjugation to glucuronic acid conjugate 4 or 
sulfate 5 and reduction to tetrahydrocurcumin (THC, 6), octahydrocurcumin (7) and 
hexahydrocurcumin (8), according to in vivo studies performed in rats and mice and also 
in studies performed in suspensions of human hepatocytes (Figure 4). Reduced 
metabolites of curcumin (1) can also be subjected to glucuronidation 25. The reduction of 
curcumin (1) occurs most likely via alcohol dehydrogenase, prior to conjugation 4. 
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Figure 4 - Curcumin metabolites. 
 
The curcumin (1) metabolism was found to be a key topic of recent research, since 
most studies indicate that its metabolites have biological activities. For instance, THC (6) 
revealed higher antioxidant activity than curcumin (1) in several assays including a linoleic 
acid autoxidation model, in the rabbit erythrocyte membrane ghost system and in a rat 
liver microsomal system 26. This metabolite 6 also inhibited radiation-induced lipid 
peroxidation in rat liver microsomes in a concentration-dependent manner 27. THC (6) 
exhibits higher antioxidant potential than curcumin (1) in most models and is now 
considered to be one of the factors responsible for the in vivo antioxidant activity of 
curcumin (1) 5. The proposed antioxidant mechanism of THC (6) is represented in 
Scheme 1 26, 28. 
A study revealed that the oral administration of curcumin (1) and THC (6) could 
reduce aberrant crypt foci and polyps formation, although THC (6) showed better 
inhibitory effect than curcumin (1), in azoxymethane-induced colon carcinogenesis; both 
compounds, curcumin (1) and THC (6), significantly decreased azoxymethane-induced 
Wnt-1 and β-catenin protein expression, as well as phosphorylation of glycogen synthase 
kinase-3β (GSK-3β) in colon tissue; and reduced the protein level of connexin-43, an 
important molecule of gap junctions, indicating that curcumin (1) and THC (6) might affect 
the intracellular communication of crypt foci 29. 
THC (6) and hexahydrocurcumin (8) showed weaker ability to inhibit 
cyclooxygenase-2 (COX-2) than curcumin (1), in a human colon epithelial cellular models 
with prostaglandin E2 production induced by phorbol ester 
30. Moreover, 
hexahydrocurcumin (8) as well as octahydrocurcumin (7) were less effective than 
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curcumin (1) in reducing the levels of inducible nitric oxide synthase (iNOS) in 
lipopolysaccharide-activated macrophages 31. 
 
 
Scheme 1 - Proposed antioxidant mechanism of THC (6). 
 
THC (6) also increases the sensitivity of HEK 293/ABCC1 cells to the multidrug 
resistance-associated protein 1 (MRP1) substrate etoposide 32. 
 
 
 
2. Multidrug resistance in cancer 
 
 
Cancer is one of the leading causes of death worldwide. According to the World 
Health Organization approximately 8.2 million deaths occurred in 2012 due to this illness. 
Unhealthy life style and aging are fundamental factors for the development of cancer. 
However, early detection and treatment can significantly increase the chances of cure 33. 
One of the causes for therapy failure is the multidrug resistance (MDR) 34. MDR 
occurs when the disease is insensitive to treatment, and it may occur either from the 
begging of the treatment or be acquired during treatment 35-36. Multiple mechanisms have 
been identified as being responsible for MDR, and although these mechanisms have been 
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intensively studied, not all of them have been completely elucidated. Cancer cells can 
become resistant to drugs by decreasing the drug influx (when the agent enters the cell by 
endocytosis or associated with intracellular carriers); in cases in which drug accumulation 
is unchanged the cell can activate detoxifying proteins, such as cytochrome P450; cells 
can promote mechanisms that repair drug induced DNA damage; disrupt apoptotic 
signaling pathways, thus, becoming resistant to drug-induced cell death; increase the 
activity and/or overexpression of efflux pumps, such as the ATP-binding cassette (ABC) 
transporters (Figure 5) 37-38. 
 
 
Figure 5 - Cellular factors responsible for drug resistance. 
 
The overexpression of ABC transporters is currently one of the most studied 
processes of MDR. ABC transporters are active transporter proteins that use the energy 
derived from the hydrolysis of ATP to ADP to transport their substrates across the cell 
membrane, maintaining cellular homeostasis and detoxifying the cell from potentially toxic 
substances 39. Currently, 49 members of the ABC transporter family have been isolated 
and identified 40. Three pumps that are commonly found to confer chemoresistance in 
cancer are P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1) and 
human breast cancer resistance protein (BCRP) 41. Thus, these transporters have been 
the target of several studies to identify novel compounds to counteract MDR. 
P-gp (encoded by MDR1 gene) consists of two homologous halves, each one with 
six hydrophobic transmembrane α-helices (which form the pathway through which the 
compounds cross the membrane) and one nucleotide binding domains located on the 
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cytoplasmic side of the membrane (which binds and hydrolyses ATP) 39. P-gp is highly 
expressed in apical surface of epithelial cells of the intestine, liver bile ductules and kidney 
proximal tubules, pancreatic ductules, adrenal gland, placenta, blood-testis barrier, and 
blood-brain barrier 39.  
MRP1 transporter (encoded by ABCC1 gene) is normally present on the basolateral 
surface of the epithelial membrane41. This transporter consists of seventeen 
transmembrane segments and two nucleotide binding domains located on the cytoplasmic 
side of the membrane37. MRP1 transporter is a mediator of MDR in breast, lung, and 
prostate cancer 42.  
BCRP (encoded by ABCG2 gene) is highly expressed in the apical surface of small 
intestines, colon epithelium, liver canalicular membrane, luminal surfaces of microvessel 
endothelium of human brain and in the veins and capillaries of blood vessels 41. BCRP 
transporter has only six transmembrane domains and one nucleotide binding domain on 
the cytoplasmic side of the membrane 37. BCRP is responsible for MDR in breast, colon, 
small cell lung, ovarian, gastric and intestinal cancers 41.  
Altogether, the tissue location of these transporters corroborates with the 
physiological role they play in protecting the susceptible organs from toxic xenobiotics. 
Many anticancer drugs are substrates of MDR transporters, conferring the cancer 
cells resistance to such treatments. Figure 6 depicts several anticancer drug substrates of 
P-gp, MRP1 and BCRP transporters. The promiscuity of these proteins is evident, since 
they are able to transport structurally and mechanistically unrelated classes of anticancer 
drugs 43. 
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Figure 6 –P-gp, MRP1, and BCRP located on the cell surface and respective anticancer 
drug substrates. 
 
 
2.1. MDR transporters inhibitors 
 
One way to overcome resistance to anticancer drugs is the administration of ABC 
transporters inhibitors that are not toxic themselves and are able to reverse resistance 
against anticancer drugs. P-gp inhibition has been extensively studied and may occur 
through: i) direct interaction with one or multiple drug-binding sites on P-gp; ii) inhibition of 
the binding of ATP to its binding site on P-gp; iii) interaction with an allosteric residue 
important for P-gp activity; iv) or even an interaction with the lipid membrane altering the 
drug-membrane interaction 44-46 (Figure 7). Many compounds have been identified as 
MDR modulators over the years. 
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Figure 7 – Different mechanisms for P-gp inhibition. 
 
The first-generation of MDR inhibitors was not specifically developed for this 
purpose, but had other pharmacological activities; also, these drugs exhibited low affinity 
for ABC transporters and higher doses were needed. Higher doses were associated with 
high toxicity levels, limiting their application. Many agents can be included in this first-
generation of MDR inhibitors: calcium channel blockers, such as verapamil; calmodulin 
antagonists; steroidal agents; protein kinase C inhibitors; immunosuppressive drugs, such 
as cyclosporine A; antibiotics, like erythromycin; antimalarials, such as quinine; 
psychotropic phenotiazines and indole alkaloids; steroid hormones and anti-steroids (e.g. 
progesterone and tamoxifen); detergents and surfactants 43, 47. 
Clinical trials with first-generation MDR modulators often failed due to side effects or 
the fact that these compounds were also substrates for ABC transporters, competing with 
the cytotoxic drug for efflux, and thus requiring high serum concentrations 47. 
Second-generation MDR modulators were designed in an attempt to reduce the side 
effects of the first-generation MDR drugs. These compounds showed better 
pharmacological profile than the first generation but they failed in clinical trials. Their 
affinity to ABC transporters was lower than expected at tolerable doses; co-administration 
of MDR chemosensitizers with anticancer drugs often interfered with clearance or 
inhibited their metabolism and excretion, leading to high plasma concentration of the 
anticancer drug, and consequently toxicity; the competition between anticancer drugs and 
MDR inhibitor for cytochrome P450 3A4 activity resulted in unpredictable pharmacokinetic 
interactions 47. R- Verapamil and dexniguldipine are examples of this second-generation 
MDR modulators 43. 
The third-generation compounds were designed to circumvent the problems 
associated with first and second-generation MDR inhibitors, based on quantitative 
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structure-activity relationships (QSAR). These inhibitors are suggested to be more potent 
and more specific than their precursors. Particularly, third generation chemosensitizers do 
not affect cytochrome P450 3A4 at relevant concentrations; they do not alter the 
pharmacokinetics of the co-administrated anticancer drug, compared to the previous 
generations extension, and so, do not require chemotherapy dose reduction 35. Some 
examples of such compounds are: elacridar (GF120918), laniquidar (R101933) 
zosuquidar (LY335979) and tariquidar (XR9576) 41. However, these inhibitors exhibited 
toxic effects in clinical trials 35. 
Although most of the compounds did not reach the purpose for which they were 
develop these three generations of MDR inhibitors helped to set ground knowledge for the 
development of novel inhibitors. In the last decade several studies have reported natural 
compounds (such curcumin, 1), marine compounds, tyrosine kinase inhibitors and 
phosphodiesterase-5 inhibitors as inhibitors of ABC transporters, which are 
mechanistically and structurally different from the three generations of inhibitors 41. The 
dual ligands approach has also been considered in order to develop molecules with dual 
antitumor and anti-Pgp activity. Indeed, by merging a scaffold with antitumor activity with a 
P-gp inhibitor scaffold, novel P-gp inhibitors with concomitant antitumor activity have been 
recently developed in the group 48.  
New strategies are being investigated in order to overcome MDR without the use of 
small molecules as pharmacological inhibitors. Downregulation of MDR transporters by 
antisense oligonucleotides is one of the strategies being studied currently. Target 
physiological mechanisms involved in regulation the of MDR proteins is another 
possibility. For example, MDR1 and cytochrome P450 3A4 gene expression are 
stimulated by certain anticancer drugs by activation of nuclear steroid and xenobiotic 
receptor (SXR) leading to drug resistance. The development of SXR antagonists that 
would be co-administrated with anticancer drugs could counteract the induction of the 
mentioned genes. MDR phenotype is sometimes associated with upregulation of 
glucosylceramide, since glucosylceramide synthase contributes to attenuate drug-induced 
formation of apoptotic ceramide. Hence antisense suppression of glucosylceramide 
synthase could significantly improve anticancer drugs pharmacological action 38. 
Anticancer drug delivery using particles and polymers could represent an interesting and 
elegant way to overcome MDR, this strategy offers a great variety of advantages: enables 
tissue specific targeting; “optical” agents for imaging and tracking; multiple payloads 
(internalization of several drugs or agents that cause tumor cell death). 
It is important to understand that multidrug resistance is a double-edged sword. On 
one hand cancer cells need to lose their drug resistance for chemotherapy to be effective. 
On the other hand, chemotherapy-sensitive non-cancerous cells need to be protected 
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from the effects of chemotherapeutic agents. Besides that, MDR modulation faces many 
other challenges. For example: the existence of other unknown multidrug resistance-
inducing molecules in cancer; the inhibition of MDR transporters could impair the normal 
function of certain organs where these MDR transporters are present and play an 
essential role in the body’s defense mechanism (e.g. liver, kidneys, gastrointestinal gland, 
adrenal gland, and blood-brain barrier). Hence, MDR inhibitors should target MDR 
transporters in a way that is tissue and/or cancer specific 34. A recently discovered 
challenge is the cells ability to release microvesicles, more specifically, microparticles that 
could carry various bioactive molecules such as proteins, like P-gp and MRP1. Thus, 
microparticles can confer and transfer MDR in cancer cells by intercellular transfer of 
functional resistance proteins, leading non-resistant cancer cells to become resistant49.  
Concluding, MDR in cancer is a complex process that needs to be overcome, 
having in mind the biological importance of MDR transporters. 
 
 
 
3. Curcumin as a multidrug resistance modulator 
 
Curcumin (1), and some other curcuminoids, have been shown to down-regulate the 
MDR1 gene expression and decrease P-gp function 23, 50-51.  
A study of the modulation of P-gp function in a MDR human cervical carcinoma cell 
line, KB-V1, showed very promising results 23. Indeed, the half maximal inhibitory 
concentration (IC50) values for curcumin (1) were similar in the KB-V1 cells (from a drug 
resistant cell line, expressing high levels of P-gp) and in the KB-3-1 cells (from the 
parental drug-sensitive cell line). 
These results indicate that curcumin (1) is not likely to be transported by P-gp. In 
addition, curcumin (1) increased the KB-V1 cellular sensitivity to vinblastine, an anticancer 
drug. It also blocked the efflux of fluorescent P-gp substrates and inhibited verapamil-
stimulated Pgp-ATPase activity in KB-V1 cells. These results may suggest that the 
binding site of curcumin (1) on P-gp overlaps with that verapamil.  Therefore, binding of 
curcumin (1) could affect the binding of other drug substrates by changing the 
conformation of P-gp 23. 
One of the undertaken studies tested the ability of curcumin (1) to revert MDR in a 
P-gp overexpressing human osteosarcoma cell line (MNNG/HOS/MTX) and also in a 
xenograft model of those cells in nude-mice 51. Curcumin (1) proved to be effective in 
down-regulating the expression of P-gp and also inhibiting the function of P-gp in vitro and 
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in vivo. To investigate these effects in vitro, several assays were performed in cells in 
culture such as determinations of alterations in the IC50 of antitumor drugs, resistance 
index (RI), P-gp expression and intracellular concentration of a fluorescent P-gp substrate. 
In addition, real time-polymerase chain reaction (real time-PCR) and Western blot assays 
showed that curcumin (1) reversed MDR of MNNG/HOS/MTX xenografted cells in nude 
mice, by down-regulating the expression of P-gp and therefore improving the sensitivity of 
osteosarcoma MDR cells to the effect of anticancer drugs (regarding inhibition of the 
xenografted cells proliferation and metastasis) 51. 
The effect of curcumin (1) on the MDR of the human gastric carcinoma cell line 
SGC7901/VCR (which is resistant to vincristine) has also been tested 50. Curcumin (1) has 
been shown to decrease the IC50 values of vincristine and to promote vincristine-mediated 
apoptosis in a dose dependent manner. Additionally, curcumin (1) increased the 
intracellular concentrations of a fluorescent P-gp substrate, but did not change the 
accumulation and efflux of such substrates in the SGC7901 drug-sensitive cells. 
Furthermore, when the resistant cell line was treated with vincristine in combination with 
curcumin (1), cells showed an increase in the activation of caspase-3 (indicative of 
apoptosis), when compared to the cells treated with vincristine alone 50.  
Another study tested the effect of sulfinosine and curcumin (1) combined 
administration in a non-small cell lung carcinoma cell line overexpressing P-gp (NCI-
H460/R, a drug-resistant cell line). The drugs exerted a synergistic tumor cell growth 
inhibitory effect and the expression of MDR-related genes (such as mdr1, gst-π and topo 
IIα) was decreased. Therefore, sulfinosine and curcumin (1) overcame MDR in the 
referred cell line in spite of the presence of a mutated p53 gene 52. 
Co-delivery of curcumin (1) and doxorubicin by lipid nanoparticles revealed a 
significant liver damage decrease in mice with diethylnitrosamine-induced hepatocellular 
carcinoma. Compared with doxorubicin loaded nanoparticles, doxorubicin/curcumin (1) 
nanoparticles decreased mRNA levels of MDR1 and protein levels of P-gp, indicating that 
curcumin (1) might reverse MDR. Increased cytotoxicity and decreased IC50 and 
resistance index (RI) also corroborate the hypothesis of synergistic effects of doxorubicin 
with curcumin (1) 53. 
Co-administration of curcumin (1) with gramidicin or ouabain selectively killed BCRP 
expressing-cells, also indicating that the synergistic effect of these compounds could be 
beneficial for MDR overcome 54. 
An in silico study has already been made, with molecular modeling and docking 
simulations, in order to study the inhibitory binding mode of curcumin (1) 55. Molecular 
docking studies inferred the binding of curcumin (1) into the substrate binding site of P-gp, 
with a binding energy of -7.66 kcal/mol, by establishing bonded and non-bonded 
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interactions with Leu32, Met35, Met36, Phe39, Phe161, Leu299, Thr300, Phe303, Ile307, 
Ser311, Met916 and Phe945 located in the membrane region (aminoacid residues which 
were proven to have drug interactions in this protein) 55. In spite of all of these findings, 
the exact molecular mechanism by which curcumin (1) exerts its effects on MDR is yet to 
be elucidated. 
 
 
 
4. Synthesis and biological activities of curcumin 
derivatives 
 
4.1. Curcumin synthesis 
 
Curcumin (1) was isolated from turmeric in 1815 56, obtained in crystalline form in 
1870, but it was not until 1910 that Lampe and Milobedzka elucidated the structure of 
curcumin (1), which was later confirmed by synthesis 4, 57-58.  The method of synthesis of 
curcumin (1) is depicted in Scheme 2 59. Later, Srinivasan separated and quantified the 
curcuminoids by chromatography 60. 
The synthesis of curcumin (1) is achieved by mixing acetylacetone (1 eq.) with 
vanillin (2 eq.). Before the addition of vanillin, boric anhydride is mixed with acetylacetone. 
Boric anhydride avoids Knoevenagel condensation of the reactive methylene group (C-3), 
by allowing the lateral methyl groups of acetylacetone to react with the aldehyde group of 
vanillin. The complex formed then reacts with vanillin. The solvent of the reaction is ethyl 
acetate (EtOAC). The n-butylamine, C4H9NH2, is a proton extracting reagent which 
activates the methyl group in acetylacetone. Tributyl borate, [CH3(CH2)3O]3B, is used to 
absorb the water produced during the reaction. The acid, HCl, decomposes the boron 
complex leading to the release of the final product, curcumin (1) 59.  
The syntheses of the curcuminoids, DMC (2) and BDMC (3), are similar to the 
synthesis of curcumin (1). The main difference lies on the precursor aldehydes that should 
be used – one molar equivalent of 4-hydrobenzaldehyde and one molar equivalent of 
vanillin to synthesize DMC (2), and two molar equivalents of 4-hydrobenzaldehyde to 
synthesize BDMC (3). 
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Scheme 2 - Synthesis of curcumin (1). Reaction conditions (i): B2O3, EtOAc, 40
o
C; (ii): n-
butylamine, 15 min; (iii): vanillin, 40
o
C, 24 h; (iv): tributyl borate; (v): HCl. 
 
 
4.2. Synthetic derivatives of curcumin 
 
Several curcumin (1) derivatives have been synthesized since the interest for this 
natural product and its biological activities were disclosed. The generalized representation 
of the pharmacophoric main structural regions of curcumin (1) is shown in Figure 8. The 
molecular structure of curcumin (1) is divided into three main regions: two substituted 
aromatic rings (A and C) linked together by a conjugated diketone (B) 61. The produced 
derivatives exhibit molecular modifications in one or more of these regions. 
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Figure 8 - Main structural moieties of curcumin (1). 
 
In some cases the synthetic strategy was different from the one depicted in Scheme 
2. A very common synthesis method is the Claisen-Schmidt condensation (described in 
the next section). The majority of the analogues were obtained by total synthesis, 
although some analogues were obtained from curcumin (1), by molecular modifications 
under conditions which do not cause its degradation such as acidic medium. 
The syntheses of the curcuminoids 1-3 and of some other derivatives, such as 
carbocyclic curcumin analogues and heteroaryl hydrazinocurcumins, can be microwave 
assisted 62-63. Microwave assisted organic reaction in such cases showed to have higher 
yields than conventional reactions, and decreased significantly the time of reaction 62-63. 
Some curcumin derivatives synthesis and respective biological activities are 
presented in the next section. The presented derivatives are some of the curcumin 
derivatives that have already been described as tumor cell growth inhibitors and multidrug 
resistance modulators. A more intensive study on curcumin derivatives and respective 
biological activities was submitted in the format of a revision manuscript. 
The curcumin derivatives were divided according to their B structural region. 
 
 
4.2.1. Derivatives with a β-dicetone moiety 
 
The synthesis and biological evaluation of a compound designated as GO-Y025 (9) 
(Figure 9) was performed by a research group, which provided evidence that the methyl 
modification of the p-hydroxyl group relative to the α,β-unsaturated ketone moiety leads to 
considerable enhancement in the growth-suppressive activity in a colon cancer cell line 
(DLD-1), in comparison to curcumin (1) 64. The synthesis of compound 9 is similar to the 
curcumin (1) synthesis, by using an appropriate aldehyde. 
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Figure 9 - Structure of GO-Y025 (1,7-bis(3,4-dimethoxyphenyl)-1,6-heptadiene-3,5-dione, 
9). 
 
Diacetylcurcumin (10) was obtained, and showed to be more stable than curcumin 
(1) in physiological medium 65. Diacetylcurcumin (10) was able to impair spindles 
formation and induced a p53- and p21CIP1/WAF1-independent mitotic arrest, in a human 
colon cancer cell line. Then, a p53/p21CIP1/WAF1-dependent inhibition of G1 to S transition 
was triggered by diacetylcurcumin (10) as a consequence of a mitotic slippage, avoiding 
post-mitotic cells from re-entering the cell cycle 65. The synthesis and structure of 
derivative 10 is shown in Scheme 3. 
 
 
Scheme 3 - Synthesis protocol of diacetylcurcumin (4-[(1E,6E)-7-(4-acetyloxy-3-
methoxyphenyl)-3,5-dioxohepta-1,6-dienyl]-2-methoxyphenyl] acetate, 12). Reaction conditions (i): 
dimethylformamide, 30 min, 80
o
C; (ii): tributylborate, 30 min, 80
o
C and then addition of n-
butylamine and 3-acetylbenzaldehyde, 4 h. 
 
A series of curcumin analogues was synthesized and evaluated as androgen 
receptor antagonists against two human prostate cancer cell lines, PC-3 and DU-145. 
Analogues 9 and 11-14 showed higher antiandrogen activity than hydroxyflutamide, which 
is the currently available drug for the treatment of this type of cancer. SAR studies 
indicated that the co-planarity of the β-diketone moiety and the presence of a strong 
hydrogen bond donor group are crucial features for the antiandrogenic activity 66-67. The 
synthesis of compound 14 is similar to that of curcumin (1) (Scheme 2), consisting in 
using appropriate aldehydes to achieve the products of interest; synthesis of compounds 
11-13 is shown in Scheme 4. 
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Scheme 4 - Structure of analogue 14 and synthesis of analogues 11-13. Reaction conditions 
(i): acetone, methyl chloroacetate, sodium iodide, reflux for 24h; (ii): acetone, RI (R= 12: 
C2H5COOCH2CH2I; 13: COOCH2CH2I), K2CO3, reflux for 48h. 11: dimethyl 2,2'-((((1E,6E)-3,5-
dioxohepta-1,6-diene-1,7-diyl)bis(2-methoxy-4,1-phenylene))bis(oxy))diacetate; 12: ethyl (E)-7-(4-
hydroxy-3-methoxyphenyl)-4-((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)-5-oxohept-6-enoate; 13: 
(E)-7-(4-hydroxy-3-methoxyphenyl)-4-((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)-5-oxohept-6-
enoic acid; 14: (1E,6E)-1-(3,4-dimethoxyphenyl)-7-(3-methoxyphenyl)hepta-1,6-diene-3,5-dione. 
 
 
4.2.2. Derivatives with a β-dicetone modified moiety 
 
Some curcumin derivatives were synthesized using the concept of bioisoterism 68. 
The ability of such derivatives to inhibit cell growth and induce apoptosis was analyzed by 
in vitro assays in the hepatocellular carcinoma HA22T/VGH cell line, breast cancer MCF-7 
cell line, and in its MDR variant MCF-7R cell line. The dioxime derivative 15 showed 
higher potency, about twice that of curcumin (1), both in the MCF-7 and MCF-7R cells. 
Indeed, derivative 15 also showed marked pro-apoptotic activity, matching its ability to 
inhibit nuclear factor-kappa B (NF-κB) activation as well as the expression of anti-
apoptotic factors (such as survivin, XIAP, Bcl-2 and Bcl-xL) 68. Synthesis of this compound 
is shown in Scheme 5. 
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Scheme 5 - Synthesis of compound 15 ((1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-
1,6-diene-3,5-dione O,O-diphenyl dioxime). Reaction conditions (i): O-benzyl-hydroxylamine 
hydrochloride in 25% K2CO3:H2O/EtOH, reflux for 25 min. 
 
 
4.2.3. Derivatives with an enone moiety 
 
The strategy followed for this type of derivatives was to eliminate the β-diketone 
moiety present in curcumin (1), and thus, to reduce the instability associated with the 
methylene group. 
In a series of studies, some molecular modifications of curcumin (1) were performed 
and the antiangiogenic activity was tested in the resulting derivatives. The general method 
of synthesis followed the Claisen-Schmidt condensation is represented in Scheme 6 and 
some of the compounds are represented in Figure 10. The biological efficacy of the 
compounds as in vitro inhibitors of endothelial cell proliferation was evaluated in SVR 
cells, an immortalized endothelial cell line 61. Out of the numerous compounds 
synthesized, compounds 16-20 showed the best antiangiogenic effects (SVR growth 
inhibition in the order of 92-98% at 3 μg/mL concentration and 94-98% at 6 μg/mL 
concentration). Some tetralone analogues were also synthesized, and the one with the 
best antiangiogenic activity was derivative 21, although the values observed for this 
compound were lower than for compounds 16-20. Curcumin (1) was also tested, for a 
comparative purpose, and presented a considerable endothelial cell growth inhibition of 
approximately 37.8% at 3 μg/mL, and 56.2% at 6 μg/mL). In order to verify the 
requirement for the enone moiety for achieving antiangiogenic activity, compound 22 was 
also synthesized and evaluated. Its relatively low level of activity (SVR growth inhibition of 
approximately 11.5% at 6 μg/mL) led to the suggestion that the enone moiety is in some 
way important for the potency of compounds 61, 69. 
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Scheme 6 - Generalized synthetic scheme for the preparation of curcumin derivatives with 
enone moieties. Reaction conditions (i): KOH, ethanol (EtOH), 5-10
o
C, and 4 h. 
 
 
Figure 10 - Derivatives 16-22. 16: chalcone; 17: 2,6-dichlorochalcone; 18: 2,6-dichloro-4’-
methylchalcone; 19: 2-naphthalene-3-phenylprop-2-en-1-one; 20: 1-phenyl-3-(pyridin-2-yl)prop-2-
en-1-one; 21: 2-(naphthale-2-ylmethylene)-tetralone; 22: 1,3-diphenyl-1-propanone. 
 
Interestingly, compounds with a chlorobenzamide moiety were found to exhibit MDR 
reversal activity, by inhibiting the drug efflux function of P-gp; based on these 
considerations, other molecular modifications of curcumin (1) were attempted 70. The 
derivatives 23-26, synthesized according to Scheme 7, did not present cytotoxicity either 
against KB cells (not-expressing P-gp) or KBV20C cells (expressing P-gp). Nevertheless, 
they significantly improved the cytotoxicity of vincristine and paclitaxel, in KBV20C cells. 
According to the obtained results, chlorobenzamides 23-26 were shown to have the 
strongest MDR reversal activity. A structure-activity relationship could be established: 
apparently one chlorine group at the meta- or para- position on benzamide increases the 
MDR reversal activity; indeed, a bulkier group at the meta- or para- position on benzamide 
may be the reason why these compounds presented promising results. To confirm that 
the MDR reversal activity of these curcumin analogues 23-26 was due to the inhibition of 
the drug efflux function of P-gp, the effect of compounds 23-26 on intracellular 
accumulation of rhodamine 123, a fluorescent P-gp substrate, was examined. Indeed, 
treatment with these compounds was enough to inhibit P-gp function and increase the 
intracellular concentration of rhodamine 123. The authors proposed that the derivatives 
23-26 were interesting starting points for the synthesis of new compounds capable of 
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causing the intracellular accumulation of anticancer drugs (thus enabling them to exert 
their cytotoxic effects) 70. 
 
 
Scheme 7 - Synthesis of compounds 23-26. Reaction conditions (i): KOH, EtOH, 40
o
C, r.t., 
10 h; (ii): Dioxane/water (1:1), the appropriate benzoyl chloride, 0
o
C, 5-7 h. 23 (4-chloro-N-(3-(3-(4-
hydroxy-3-methoxyphenyl)-acryloyl)-phenyl)-benzamide); 24 (2,4-dichloro-N-(3-(3-(4-hydroxy-3-
methoxyphenyl)-acryloyl)-phenyl)-benzamide); 25 (3,4-dichloro-N-(3-(3-(4-hydroxy-3-
methoxyphenyl)-acryloyl)-phenyl)-benzamide); 26 (3,5-dichloro-N-(3-(3-(4-hydroxy-3-
methoxyphenyl)-acryloyl)-phenyl)-benzamide).  
 
An interesting set of derivatives with 2-ethylamino groups in a chalcone structure 
were synthesized (27-28), with the aim of stimulating the cytotoxicity of tumor necrosis 
factor (TNF)-related apoptosis-inducing ligand (TRAIL) using TRAIL-resistant human 
CRT-MG astroglioma cells 71. The synthetic strategy followed was the Huisgen 1,3-
cycloaddition between several alkynes and an intermediate. The two compounds depicted 
in Scheme 8 showed the most promising results as TRAIL sensitizers. Glioblastoma 
multiforme is a human malignant brain tumor known to be very aggressive and has a high 
mortality rate. Since co-treatment of glioblastoma multiform cells with a chemo-sensitizer 
and TRAIL is more efficient than TRAIL alone, these two compounds have the potential to 
be used in combination therapy for brain tumors 71-72. 
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Scheme 8 - Synthesis of compounds 27-28. Reaction conditions (i): 40% KOH, EtOH, r.t., 
10 h; (ii) the correspondent alkynes, sodium ascorbate (2.5 eq.), CuSO4 (1 eq.), 
chloroform/EtOH/H2O (5:3:1), r.t., 5 h. 27 ((E)-3-(4-(diethylamino)phenyl)-1-(3-(4-(2-hydroxypropan-
2-yl)-1H-1,2,3-triazol-1-yl)phenyl)prop-2-en-1-one) and 28 ((E)-1-(3-(4-(4-bromophenyl)-1H-1,2,3-
triazol-1-yl)phenyl)-3-(4-(diethylamino)phenyl)prop-2-en-1-one). 
 
 
4.2.4. Derivatives with a dienone moiety 
 
The strategy followed to obtain this type of derivatives was also the elimination of 
the β-diketone moiety in order to reduce curcumin (1) instability. The compounds in this 
category were synthesized by Claisen-Schmidt condensation, according to Scheme 9, 
which represents one of the most popular methods to obtain curcumin analogues. 
 
 
Scheme 9 - Generalized synthetic scheme for the preparation of curcumin derivatives with a 
dienone moiety. The ketone could be a cyclohexanone (n=3), a cyclopentanone (n=2), or acetone 
(n=0). Reaction conditions (i): KOH, EtOH, 5
o
C, 10 h. 
 
Compounds 29-32 were obtained according to Scheme 9 and their efficacy as in 
vitro inhibitors of endothelial cell proliferation was evaluated with the SVR cells, an 
immortalized endothelial cell line. Compounds 29-31 presented interesting results (SVR 
growth inhibition in the order of 90-94% at 3 μg/mL concentration and 96-98% at 6 μg/mL 
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concentration). Additionally, derivative 32 with a simpler structure was produced, which 
showed similar results to compounds 29-31 (SVR growth inhibition of 96.6% at 3 μg/mL 
concentration and 97.7% at 6 μg/mL concentration). Derivatives 29-32 structures are 
represented in Figure 11. In another study, derivative 31 also showed antioxidant activity 
73. 
 
 
Figure 11 - Derivatives 29-32. 29: 2,6-di-benzylidenecyclohexan-1-one; 30: 2,6-bis(pyridin2-
ylmethylene)cyclohexa-1-one; 31: 2,6-bis(4-hidroxi-3-methoxybenzylidene)cyclohexan-1-one; 32: 
1,5-diphenylpenta-1,4-dien-3-one. 
 
A dienone derivative designated GO-035 (33) was found to have a stronger effect 
than curcumin (1) in suppressing the growth of the cancer cell line DLD-1 64. The growth-
suppressive activity of this compound was tested in other cancer cell lines, such as the 
ones derived from tumors of the stomach (GCIY, SH10TC), lung (LK87), breast (MCF7), 
ovary (OVK18), prostate (PC3), pancreas (PK9), bile duct (HuCCT1), thyroid gland 
(8505c), skin (A431), kidney (ACHN), liver (HepG2) and melanoma (G361). Curcumin (1) 
and its derivative 33 presented growth-suppressive activity in all types of the cancer cell 
lines tested, with IC50 values ranging from 4.0 to 9.0 μmol/L, and from 0.6 to 7.0 μmol/L, 
respectively. Compound 33 also showed a stronger potential than curcumin (1) for 
causing downregulation of some oncoproteins, such as β-Catenin, ErbB-2-, c-Myc, Cyclin 
D1 and K-Ras 64. Consecutively, compounds designated GO-Y078, 030 and 098 
(derivatives 34-36 respectively, Figure 12) were developed and revealed at least 10 times 
higher growth-suppressive potential than curcumin (1) in several cell lines such as the 
ones derived from tumors of the stomach (GCIY, SH10TC), colon (HCT116, DLD1 and 
SW680), lung (A549), pancreas (PK1), kidney (ACHN), liver (HUH7), ovary (OVK18), 
breast (MCF7), skin (A431), bile duct (HuCCT1), thyroid (8505c), melanoma (G361), and 
prostate (PC3) 74. It is known that, in these cancer cell lines, high activation levels of NF-
κB can lead to protection from apoptosis and that NF-κB activation can occur in response 
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to certain inflammatory signals, such as tumor necrosis factor- α (TNF-α) 74-76. Since it had 
previously been shown that curcumin (1) inhibited NF-κB transactivation 77, in this work it 
was shown that the derivatives GO-Y078 (34), 030 (35) and 098 (36) decreased TNFα-
induced NF-κB transactivation at a concentration of 2 μM 74. Synthesis of such derivatives 
is similar to the one depicted in Scheme 9. 
 
 
Figure 12 - Structure of GO-035 (1,5-bis(4-hydroxy-3-methoxyphenyl)penta-1,4-dien-3-one, 
33), GO-Y078 (1,5-bis(3,4,5-trimethoxyphenyl)penta-1,4-dien-3-one, 34), GO-Y030 (1,5-Bis(3,5-
bis(methoxymethoxy)phenyl)-1,4-pentadien-3-one, 35), GO-Y098 (1-(3-hydroxyphenyl)-5-(3,4,5-
trimethoxyphenyl)penta-1,4-dien-3-one, 36). 
 
Compound 33 was investigated in an in silico study for its properties as a possible 
multidrug resistance associated protein 5 (MRP5) inhibitor for the efflux of hyaluronan 
from fibroblasts. Hyaluronan is overproduce in many pathologies, including, inflammation, 
metastasis, and ischemia. Currently, there is no drug able to attenuate hyaluronan 
production. Virtual docking identified compound 33 (from among 120 compounds) as the 
best hyaluronan export inhibitor 78. 
A compound designated GL63 (Figure 13, 37) was studied for its ability to induce 
apoptosis in the human hepatocellular carcinoma cell line HepG2. Derivative 37 appeared 
to be more potent than curcumin (1) in the inhibition of HepG2 cellular proliferation and 
induction of cellular apoptosis 79. Its synthesis is similar to the one shown in Scheme 9. 
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Figure 13 - Structure of compound 37 ((1E,4E)-1,5-bis(2-bromophenyl)penta-1,4-dien—
one). 
 
Many compounds were synthesized and studied for their tumor cell growth inhibitory 
activity against BGC823, CNE, HL-60, KB, LS174T, PC3 and HeLa human tumor cell 
lines (Scheme 10, compounds 38-64, and 31) 80. This study proposed some ideas 
concerning SAR: i) curcumin derivatives with an acetone or cyclohexanone linker 
exhibited much higher activities than the compounds with a cyclopentanone linker; ii) 
particularly at the 2’-position, strong electron-withdrawing substituents may increase 
bioactivity; iii) at the 4’-position, weak electron-donating substituents may increase the 
tumor cell growth inhibitory activity of the compound, and strong electron-withdrawing 
ones may reduce it; iv) the introduction of an heteroatomic ring does not cause significant 
changes in the ability of the compound to inhibit tumor cell growth 80. 
 
 
Scheme 10 - Synthesis of derivatives 38-63. Reaction conditions (i): NaOCH3, methanol 
(MeOH), r.t., 20 min. 38: 2,5-bis(2-methoxybenzylidene)cyclopentan-1-one; 39: 2,5-bis((E)-4-(3-
(dimethylamino)propoxy)benzylidene)cyclopentan-1-one; 40: 2,5-bis((E)-4-
fluorobenzylidene)cyclopentan-1-one; 41: 2,5-bis((E)-2-bromobenzylidene)cyclopentan-1-one; 42: 
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2,5-bis((E)-2-(trifluoromethyl)benzylidene)cyclopentan-1-one; 43: 1,5-bis(2,3-
dimethoxyphenyl)penta-1,4-dien-3-one; 44: 1,5-bis(1,3-dihydroisobenzofuran-5-yl)penta-1,4-dien-
3-one; 45: 1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one; 46: 1,5-bis(3,4,5-
trimethoxyphenyl)penta-1,4-dien-3-one; 47: 1,5-bis(2,5-dimethylphenyl)penta-1,4-dien-3-one; 48: 
1,5-bis(4-(tert-butyl)phenyl)penta-1,4-dien-3-one; 49: 1,5-bis(4-fluorophenyl)penta-1,4-dien-3-one; 
50: 1,5-bis(2-bromophenyl)penta-1,4-dien-3-one; 51: 1,5-bis(2-chlorophenyl)penta-1,4-dien-3-one; 
52: 1,5-bis(2-(trifluoromethyl)phenyl)penta-1,4-dien-3-one; 53: 1,5-di(thiophen-2-yl)penta-1,4-dien-
3-one; 54: 1,9-diphenylnona-1,3,6,8-tetraen-5-one; 55: 2,6-bis((E)-4-hydroxy-3-
methoxybenzylidene)cyclohexan-1-one; 55: 2,6-bis((E)-3,4,5-trimethoxybenzylidene)cyclohexan-1-
one; 57: 2,6-bis((E)-2,5-dimethylbenzylidene)cyclohexan-1-one; 58: 2,6-bis((E)-4-
fluorobenzylidene)cyclohexan-1-one; 59: 2,6-bis((E)-3-bromobenzylidene)cyclohexan-1-one; 60: 
2,6-bis((E)-2-fluorobenzylidene)cyclohexan-1-one; 61: 2,6-bis((E)-2-chlorobenzylidene)cyclohexan-
1-one; 62: 2,6-bis((1-methyl-1H-pyrrol-2-yl)methylene)cyclohexan-1-one; 63: 2,6-bis((E)-3-
phenylallylidene)cyclohexan-1-one. 
 
Other authors synthesized four dienone cyclopropoxy curcumin derivatives 
(compounds 64-67, Scheme 11) and evaluated their antitumor and antiangiogenic effects 
in vivo, on mouse Ehrlich ascites tumor. These compounds increased the life span of 
tumor-bearing mice, with a corresponding significant reduction in ascites volume and cell 
number and increase in apoptotic bodies in Ehrlich ascites tumor cells. Compounds 64-67 
also reduced microvessels density, associated with angiogenesis 81. 
 
 
Scheme 11 - Synthesis of four cyclopropoxy curcumin derivatives 64-67. Reaction 
conditions (i): dimethylformamide, K2CO3, cyclopropyl bromide, 60
o
C, 6 h. 64: 1,5-bis(4-
cyclopropoxy-3,5-dimethoxy-phenyl)-penta-1,4-dien-3-one; 65: 1,5-bis(4-cyclopropoxy-3-
methoxyphenyl)-penta-1,4-dien-3-one; 66: 1,5-bis(4-cyclopropoxy-phenyl)-penta-1,4-dien-3-one; 
67: 1,5-bis(4-cyclopropoxy-3,5-dimethylphenyl)-penta-1,4-dien-3-one. 
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In a different study some novel curcumin derivatives 68-77 (Figure 14 and Scheme 
12) were synthesized and their ability to inhibit tumor cell growth together with 
antiangiogenic activity was evaluated. Most of the analogues exhibited a moderate tumor 
cell growth inhibitory activity 82. Derivatives 73, 74 and 75 presented high inhibition of 
tumor cell growth in an in vitro anticancer cell line screen. This screen based on 
evaluation of cell growth inhibition revealed that these compounds were more potent than 
cisplatin. In an independent in vitro screen, the same derivatives and analogues 69-72 
and 75 also demonstrated high degree of cytotoxicity to tumor cells. Derivatives that were 
effective in the anticancer screens, which were based on tumor cell growth inhibition, were 
also effective in the in vitro antiangiogenesis assays 82. Compounds 69, 72 and 74-76 
were the most potent in this assay. Compound 76 was almost as potent as the TNP-470, 
an antiangiogenic drug. This compound effectively reduced the size of human breast 
tumors grown in mice and presented little toxicity. These data suggest that the 
symmetrical α,β-unsaturated ketone structure found in these novel compounds shows 
increased in vitro tumor cell growth inhibitory activity and antiangiogenic activity, when 
compared to the β-diketone structure of curcumin (1). ortho-Substitution such as in 
derivatives 69, 73, 74, 75 and 76, seems to favor the activity of these analogues. 
Compounds with substitutions on meta- or para-positions, such as 68 and 70, are less 
active. The presence of an heteroatom in the cyclic ketone portion seems to increase the 
tumor cell growth inhibitory activity and antiangiogenic activity 82. Synthesis of such 
derivatives is similar to the one depicted in Scheme 9, except for derivative 77, which 
resulted from the reduction of curcumin (1) and which synthesis is shown in Scheme 12. 
 
 
Figure 14 - Derivatives 68-76. 68: 1,5-bis(4-hydroxyphenyl)-penta-1,4-dien-3-one; 69: 1,5-
bis(2-hydroxyphenyl)-penta-1,4-dien-3-one; 70: 1,5-bis(3-hydroxyphenyl)-penta-1,4-dien-3-one; 71: 
1,5-bis(2-methoxyphenyl)-penta-1,4-dien-3-one; 72: 1,5-bis(2-acetylphenyl)-penta-1,4-diene-3-one; 
73: 2,6-bis(2-hydroxybenzylidene)-cyclohexanone; 74: 3,5-bis(2-hydroxybenzylidene)-tetrahydro-4-
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H-pyran-4-one; 75: 3,5-bis(2-hydroxybenzylidene)-1-methyl-4-piperidone; 76: 3,5-bis(2-
fluorobenzylidene)-piperidin-4-one, acetic acid salt. 
 
 
 
Scheme 12 - Synthesis of derivative 77 (2,2'-(3-hydroxypentane-1,5-diyl)diphenol). Reaction 
conditions (i): EtOH, Raney nickel as a catalyst, 45 psi, 4h. 
 
A total of thirty two heteroatomic analogues with dienone linkers were synthesized 
and their cytotoxicity against two human androgen-independent-prostate cancer cell lines 
(PC-3 and DU-145) was shown to be higher than curcumin (1) 83. The synthesis of these 
compounds is similar to the one represented in Scheme 9 and is depicted in Scheme 13, 
Scheme 14, and Scheme 15, according to the dienone linker. 
 
 
Scheme 13 - Synthesis of compounds 78-86. Reaction conditions (i): NaOCH3, MeOH, r.t., 
4h. 78: (3E, 5E)-1-methyl-3,5-bis((1-methyl-1H- imidazole-2-yl)methylene)piperidin-4-one; 79: (3E, 
5E)-1-methyl-3,5-bis((1-isopropyl-1H- imidazole-2-yl)methylene)piperidin-4-one; 80: (3E, 5E)-3,5-
bis((1-(sec-butyl)-1H-imidazil-2-yl)methylene)-1-methylpiperidin-4-one; 81: (3E, 5E)-1-methyl-3,5-
bis((1-methyl-1H-pyrazol-5-yl)methylene)piperidin-4-one; 82: (3E, 5E)-1-methyl-3,5-bis((thiazole-2-
yl)methylene)piperidin-4-one; 83: (3E, 5E)-1-methyl-3,5-bis((thiazole-4-yl)methylene)piperidin-4-
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one; 84: (3E, 5E)-1-methyl-3,5-bis((2-methyloxazol-4-yl)methylene)piperidin-4-one; 85: (3E, 5E)-1-
methyl-3,5-bis((5-methylisoxazol-3-yl)methylene)piperidin-4-one; 86: (3E, 5E)-1-methyl-3,5-bis((3-
methylisoxazol-5-yl)methylene)piperidin-4-one. 
 
 
Scheme 14 - Synthesis of compounds 87-96. Reaction conditions (i): NaOCH3, MeOH, r.t., 
4h. 87: (2E, 6E)-2,6-bis((1-methy-1H-imidazol-2-yl)methylene)cyclohexanone; 88: (2E, 6E)-2,6-
bis((1-isopropyl-1H-imidazol-2-yl)methylene)cyclohexanone; 89: (2E, 6E)-2,6-bis((1-(sec-butyl)-1H-
imidazol-2-yl)methylene)cyclohexanone; 90: (2E, 6E)-2,6-bis((1-isobutyl-1H-imidazol-2-
yl)methylene)cyclohexanone; 91: (2E, 6E)-2,6-bis((1-methy-1H-pyrazol-5-
yl)methylene)cyclohexanone; 92: (2E, 6E)-2,6-bis((thiazole-2-yl) methylene)cyclohexanone; 93: 
(2E, 6E)-2,6-bis((thiazol-4-yl)methylene)cyclohexanone; 94: (2E, 6E)-2,6-bis((2-methyloxazol-4-
yl)methylene)cyclohexanone; 95: (2E, 6E)-2,6-bis((5-methylisoxazol-3-
yl))methylene)cyclohexanone; 96: (2E, 6E)-2,6-bis((3-methylisothiazol-5-
yl)methylene)cyclohexanone. 
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Scheme 15 - Synthesis of compounds 97-107. Reaction conditions (i) for compounds 97 and 
98: NaOCH3, MeOH, 4-18 h. Reaction conditions (i) for compounds 99-107: K2CO3, toluene-EtOH-
water (4:4:2), 70
o
C, 12 h. 97: (1E,4E)-1,5-bis(1-methyl-1H-imidazol-2-yl)penta-1,4-dien-3-one; 98: 
(1E,4E)-1,5-bis((1-isopropyl-1H-imidazol-2-yl)penta-1,4-dien-3-one; 99: (1E,4E)-1,5-bis(1-(sec-
butyl)-1H-imidazol-2-yl)penta-1,4-dien-3-one; 100: (1E,4E)-1,5-bis(1-isobutyl-1H-imidazol-2-
yl)penta-1,4-dien-3-one; 101: (1E,4E)-1,5-bis(1-methyl-1H-pyrazol-5-yl)penta-1,4-dien-3-one; 102: 
(1E,4E)-1,5-di(thiazol-2-yl)penta-1,4-dien-3-one; 103: (1E,4E)-1,5-di(thiazol-4-yl)penta-1,4-dien-3-
one; 104: (1E,4E)-1,5-bis(2-methyloxazol-4-yl)penta-1,4-dien-3-one; 105: (1E,4E)-1,5-bis(5-
methylisoxazol-3-yl)penta-1,4-dien-3-one; 106: (1E,4E)-1,5-bis(3-methylisoxazol-5-yl)penta-1,4-
dien-3-one; 107: (1E,4E)-1,5-di(pyridin-2-yl)penta-1,4-dien-3-one. 
 
From these compounds, all showed higher effect than curcumin (1) against PC-3 
cells, except for compound 80. In addition, compounds 78-80, 82, 83, 84, 88, 89, 92, 93, 
95, 97-103, and 105-107 exhibited higher cytotoxicity than curcumin (1) towards DU-145 
cells. Moreover, analogues 99, 100, 107 also showed impressive cytotoxic effects against 
three other tumor cell lines: MDA-MB-231, HeLa and A549, with IC50 values between 50 
nM and 390 nM. These three potent curcumin analogues were tested for their cytotoxic 
effect towards MCF-10A normal mammary epithelial cells and were shown to have no 
apparent cytotoxicity 83. From this work, the authors concluded that nitrogen-containing 
heteroatomic rings seem to be promising bioisosteres of the methoxyphenol motif in 
curcumin (1) 83. 
Recently, during the elaboration of this thesis a set of heterocyclic cyclohexanone 
derivatives of curcumin (1) was synthesized and tested for their cytotoxicity and MDR 
transporters inhibitory activity. Compound 109, 101, 111, 113, and 114 exhibited potent 
cytotoxicity towards MDA-MB-231 cells and inhibition of NF-κB activity in K562 cells. 
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Compound 110, 111, and 114 exhibited strong cytotoxicity not only in MBA-MB-231 cell 
line, but also MDA-MB-468 and SkBr3 cell lines. Particularly, derivative 111 caused 43% 
MDA-MB-231 cells to undergo apoptosis after 18 h exposure 84. Analogue 109, 31 
(Scheme 10 or Figure 11), and 162 were able to inhibit BCRP transporters. Instead, 
analogue 115 inhibited P-gp and analogue 31 inhibited MRP1 and MRP5 85. Synthesis of 
compounds 108-115 is depicted in Scheme 16. 
 
 
Scheme 16 – Synthesis of derivatives 108-115. Reaction conditions (i): EtOH, NaOH 1M, 18 
h, r.t.; (ii): MeOH, NaOCH3, 5M, 18 h, r.t. 108: (2E,6E)-2,6-bis(pyridin-3-ylmethylene)cyclohexan-1-
one; 109: 2,6-bis((E)-2,5-dimethoxybenzylidene)cyclohexan-1-one ; 110: (3E,5E)-1-methyl-3,5-
bis(pyridin-3-ylmethylene)piperidin-4-one; 111: 1-methyl-3,5-bis((E)-3,4,5-
trimethoxybenzylidene)piperidin-4-one; 112: 3,5-bis((E)-2-fluoro-4,5-dimethoxybenzylidene)-1-
methylpiperidin-4-one; 113: 3,5-bis((E)-2,5-dimethoxybenzylidene)-1-methylpiperidin-4-one; 114: 
(2E,4E)-8-methyl-2,4-bis(pyridin-3-ylmethylene)-8-azabicyclo[3.2.1]octan-3-one; 115: 8-methyl-2,4-
bis((E)-3,4,5-trimethoxybenzylidene)-8-azabicyclo[3.2.1]octan-3-one. 
 
EF24 (116, Figure 13) is a curcumin derivative that greatly inhibits cisplatin-resistant 
human ovarian cancer cellular proliferation 86. The inhibitory effect of EF24 (116) on 
cellular proliferation is associated with G2/M checkpoint protein levels. The tumor cell 
growth inhibitory effect of EF24 (116) in breast cancer cells has also been partially 
attributed to redox-mediated induction of apoptosis. Also, EF24 (116) activated the 
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phosphorylated phosphatase and tensin homolog (PTEN) and up-regulated total PTEN 
expression through the inhibition of ubiquitin-mediated PTEN degradation. Suppression of 
PTEN with small interfering RNAs (siRNAs) resulted in a significant reduction of p53 and 
p21 levels and activated Akt phosphorylation at Ser473 and Thr308, resulting in decreased 
apoptosis and increased cell survival. In contrast, the overexpression of PTEN 
significantly induced apoptosis. In this study, it was suggested that EF24 (116) induced a 
substantial increase in PTEN expression. The up-regulation of PTEN inhibited Akt and 
MDM2, which increased the levels of p53, thus inducing G2/M arrest and apoptosis 
86. 
EF24 (116) synthesis is similar to the one depicted in Scheme 9. 
 
 
Figure 15 - Structure of compound 116 (3,5-bis((E)-2-fluorobenzylidene)piperidin-4-one, 
EF24). 
 
Overall, several dienone analogues such as anelar isosters or halogenated 
derivatives were shown to be promising compounds in several bioactivities. 
Heterocycles are a privileged chemical source of bioactive compounds. Several 
compounds were synthesized with heterocyclic moieties instead of the carbonyl group in 
curcumin (1) displaying promising results in several activities such as free radical 
scavenging activity, antioxidant, and antitumor activity 87; antibacterial activity 88; 
antimalarial activity 89, among others. 
Over the past few years, many research groups have focused their efforts in 
improving curcumin (1) bioavailability by slowing its metabolism, increasing solubility or 
cellular uptake by synthesizing curcumin bioconjugates. This strategy was based on 
merging curcumin (1) with aminoacids 90, nucleosides 91, dipeptides, fatty acids and folic 
acid 92. The synthesized compounds showed a vast range of bioactivities such as 
antiproliferative, antimicrobial, and antiviral. 
In addition to the synthetic analogues, several other strategies have been successful 
in the improvement of curcumin (1) bioavailability. Adjuvants, nanoparticles, liposomes, 
micelles and phospholipids are some of the attempted strategies 5, 93-101. 
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CHAPTER II: 
RESULTS AND DISCUSSION
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1. Synthesis and structure elucidation 
 
Curcumin (1) has shown to be a promising compound in therapeutics; however, the 
chemical stability and extensive metabolism are substantial limitations to its potential use. 
Therefore, we aimed to synthesize three mono-carbonyl building blocks chemically more 
stable, eliminating the unstable portion of the molecule. The selected building blocks had 
already been synthesized and showed improved stability comparing to curcumin (1) 80. In 
order to improve the P-gp modulatory activity different substitution patterns were 
introduced in the phenolic groups. The substitution patterns include alkylated groups (with 
an alkene and alkyne terminal portion), a sugar, amines, carbamates and an ester. These 
substitution patterns were selected considering the chemical diversity they represent. 
Specifically the amines are well known for their drug-like properties, and the nitrogen 
atom, charged at physiological pH, has often been considered to be a symbol of P-gp 
substrates and inhibitors 102. 
 
 
1.1. Synthesis of 4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one) (117) 
and 1,5-bis(4-hydroxy-3-methoxyphenyl)penta-1,4-dien-3-one (33) 
 
The synthetic approach used for the synthesis of the mono-carbonyl analogues of 
curcumin, was the Claisen-Schmidt condensation. The synthesis of these building blocks, 
4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one) (117) and 1,5-bis(4-hydroxy-3-
methoxyphenyl)penta-1,4-dien-3-one (33), has been previously described 69, 82. One 
equivaet of vanillin was allowed to react one equivalent with acetone to afford compound 
117 (Scheme 17a) and two equivalent of vanillin with one equivalent of N-methyl-
piperidone to afford compound 33 (Scheme 17b). Scheme 17 summarizes the reaction 
conditions and the results obtained in the synthesis of compound 117 and 33. Regarding 
compound 117 synthesis, originally, the goal was to obtain a building block with two 
aromatic rings (33, Scheme 18). With the conditions depicted in Scheme 17a, the major 
product formed was compound 117, however, other by-product was formed. The major 
by-products were isolated by preparative chromatography, and analysis by 1H NMR lead 
to the conclusion that this by product was not the expected 1,5-bis(4-hydroxy-3-
methoxyphenyl)penta-1,4-dien-3-one (33, Scheme 18), and no further investigation was 
performed. Due to the satisfactory yield in obtaining compound 117 and the convenient 
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purification by crystallization (without need of chromatographic purification) the enone 117 
was selected as a suitable model for further molecular modifications. 
Regarding compound 33 synthesis, originally, the goal was to obtain the building 
block depicted in Scheme 19. Although the purification process followed for compound 
117 was exactly as the one described in the literature for compound 33 73, the results 
were sightly different from the one described in the literature for compound 3,5-bis((E)-4-
hydroxy-3-methoxybenzylidene)-1-methylpiperidin-4-one (118) 82, since after neutralizing 
the solution, could not be observed precipitate formation. Thus, the crude product was 
submitted to a liquid-liquid extraction, and solid-liquid anionic exchange followed by a 
column chromatography which can also explain the low isolated yield for compound 33. 
During the purification process no acetone was used, which could have triggered the 
reaction leading to the synthesis of compound 33. However, the purified compound was 
not the expected one and its synthesis could have been the outcome of base and acid 
usage through the purification process. 
 
Scheme 17 – Reaction conditions and results for the synthesis of compounds 117 and 33 
(r.t.= room temperature). 
 
 
Scheme 18 – Described reaction conditions for the synthesis of compound 33 
73
. 
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Scheme 19 – Described reaction conditions for the synthesis of 118 
82
. 
 
Comparing the yields obtained for the compounds 117 and 33 building blocks it is 
possible to infer that the reaction between vanillin and N-methyl-piperidone occurred with 
difficulties, probably due to steric hindrance. Due to low yielding reaction to obtain 
compound 33, the synthesis of derivatives was not further pursuit with this building block. 
Thus, from the above obtained results, compound 117 was selected as a potential 
stable model of curcumin (1) to pursuit the synthesis of derivatives.  
Structure characterization of the two synthesized compound 117 and 33 was 
performed by melting point, UV-Visible (UV-Vis), infrared (IR), 1H and 13C NMR 
spectroscopy techniques and mass spectrometry (MS) techniques. In the case of 
compound 33, further analysis by HRMS was performed to unequivocally establish the 
structure. Melting point can be consulted in page 91 and UV-Vis data in page 77. 
 
The IR data of these two compounds were in accordance with the molecular 
modifications performed (Table 1). The presence of bands between 960-990 cm-1 typical 
of the sp2 C-H bond of a trans disubstituted alkene (bend pattern) corroborate with the 
hypothesis of the reaction occurring successfully. The aldehyde band for the C-H bond at 
around 2800-2700 cm-1 (bend pattern) was only observed for the precursor compound 
vanillin which is also in accordance with the performed molecular modifications for 
compound 117 and 33. Additionally, IR spectra revealed the presence of a large band 
corresponding to stretching vibration of hydroxyl groups at, 3200-3500 cm-1. 
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Table 1 - IR data of compound 117 and 33. 
Group 
 (cm
-1
) 
Vanilin 117 33 
OH 3000-3400 3200-3500 3200-3600 
C-H (Stretch sp
2)
 ----- 3002 2934 
C-H (Aldehyde strectch) 2857 ----- ----- 
C=O 1665 1637 1639 
C=C (Stretch Ar) 1588, 1509, 1465 1583, 1519, 1452 1587, 1511, 1449 
C-O (Acyl) 
1299, 1266, 1199, 
1171, 1154 
1297, 1267, 1226, 
1188 
1267, 1159 
C-O (Alcoxy) 1124, 1039 1124, 1026 1104, 1029 
C-H (Bend alkene sp
2 
- trans) ----- 981 981, 852, 811 
 
 
The 1H and 13C NMR data of compounds 117 and 33 are depicted in Table 2 and 
Table 3, respectively. 
According to the 1H NMR spectra of compounds vanillin (data not shown)103, 
compounds 117 and 33 (Table 2) only the precursor vanillin showed signals in the 
aldehyde region (δH 10-9 ppm), indicating that the bond between the aldehyde and the 
ketones was formed successfully in the synthesized compounds 117 and 33. Also, the 
signals corresponding to vinyl hydrogens are in accordance with the molecular 
modifications introduced. In compound 117, the signals corresponding to two vinyl protons 
H-2 and H-3 split each other into two doublets, one centered at δH 7.45 ppm more 
deshielded than the phenyl protons and the other at δH 6.59 ppm more shielded than the 
phenyl protons. The H-3 proton, attached to the carbon adjacent to the phenyl ring, shows 
a higher chemical shift when compared to H-2 proton, as it should be in a deshielding 
area of the anisotropic field generated by the π electrons of the aromatic ring. The 
coupling constant observed for the signal corresponding to the H-3 doublet was of 16.2 
Hz, a common value for trans proton-proton coupling across a double bond 104. 
Multiplicities and chemical shifts  of signals corresponding to protons H-2 and H-3 in 
compound 33 are similar to the same signals of compound 117. Similarly to the precursor 
vanillin 103, 1H NMR spectra of compounds 117 and 33 showed signals corresponding to 
the aromatic protons: H-2’, H-5’, and H-6’ with the expected multiplicities (d, d and dd), as 
well as the hydroxyl group (H-4’) and methoxyl group (H-3’’). The signal at δH 2.37 ppm 
integrating for three protons present in compound 117 spectra was not in agreement with 
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the originally proposed structure (compound 33) but the latter proposed structure of 
compound 117. This signal was crucial to determinate compound 117 structure. 
 
Table 2 - 
1
H NMR data of compounds 117 and 33.
 
 
 
117 
 
 
33 
Proton* δH (values in ppm relative to Me4Si as an internal reference)** 
H-3 7.45, 1H, d, J= 16.2 7.68, 2H, d, J= 15.5 
H-6’ 7.09, 1H, dd, J= 8.1 and 1.9 7.18, 2H, dd, J= 8.2 and 1.8 
H-2’ 7.05, 1H, d, J= 1.9 7.11, 2H, d, J= 1.8 
H-5’ 6.93, 1H, d, J= 8.1 6.92, 2H, d, J= 8.2 
H-2 6.59, 1H, d, J= 16.2 6.94, 2H, d, J= 15.5 
H-4’ 6.00, 1H, brs 5.99, 2H, brs 
H-3’’ 3.92, 3H, s 3.95, 6H, s 
H-1’’ 2.37, 3H, s ----- 
* Numbering of atoms was attributed for NMR assignments. 
** J values are presented in Hz. 
 
 
13C NMR assignments of the hydrogenated carbons were determined by 2D 
heteronuclear single quantum correlation (HSQC) and the chemical shifts of the carbon 
atoms not directly bonded to hydrogen atoms were deduced by heteronuclear multiple 
bond correlation (HMBC) experiments (Table 3 and Figure 16). HMBC spectra also 
corroborated with the proposed structure and that the compound synthesized was in fact 
the derivative 117. The NMR spectroscopic data are in accordance with the described in 
literature for compound 117 105 and 33 106. 
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Table 3 - 
13
C NMR data of compounds 117 and 33. 
 
 
117 
 
33 
Carbon* δC (values in ppm) 
C-1 198.7 188.9 
C-4’ 148.4  148.2 
C-3’ 147.0 147.2 
C-3 144.0 143.3 
C-1’ 126.8 127.5 
C-2 124.9 123.4 
C-6’ 123.6 123.3 
C-5’ 114.9 114.9 
C-2’ 109.4 109.8 
C-3’’ 56.0 56.0 
C-1’’ 27.3 ----- 
* Numbering of atoms was attributed for NMR assignments. 
 
 
Figure 16 - Connectivities found in the HMBC spectra of compound 117. 
 
The electron impact-mass spectrometry (EI-MS) spectra were obtained in a gas 
chromatography-mass spectrometry (GC-MS) equipment and the molecular ion peak and 
base peak for the trimethylsilyl derivative of 117 was found to be 264 m/z and 233 m/z, 
respectively. Considering that the compound had to be derivatized for GC-MS analysis, 
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which involved the reaction of N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) with 
the phenol group, the correspondent value subtracting the molecular weight of the 
trimethylsilyl group would be 192 and 161, respectively. Therefore, the molecular ion peak 
is in agreement with the molecular weight of the proposed compound 117. The HRMS-ESI 
analysis of compound 33 gave the accurate molecular mass of 327.12265 and the 
molecular formula of C19H19O5. 
 
 
1.2. Synthesis of alkylated derivatives of compound 117, 
compounds119 and 120. 
 
The synthesis of the two alkylated derivatives of compound 117, 4-(4-(allyloxy)-3-
methoxyphenyl)but-3-en-2-one (119) and 4-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)but-
3-en-2-one (120), followed a synthetic microwave (MW) assisted approach based on a 
nucleophilic substitution bi-molecular (SN2) reaction
107. One equivalent of allyl bromide 
and propargyl bromide reacted with one equivalent of 117 to afford compound 119 or 120, 
respectively. Scheme 20 summarizes the reaction conditions and the results obtained. 
Both compounds were purified by column chromatography, and compound 120 was 
further crystallized from a mixture of diethylether:petroleum ether in order to isolate the 
compound. 
 
 
Scheme 20 – Reaction conditions and results for the synthesis of compounds 119 and 120. 
 
In these two reactions, the major products formed were compound 119 and 120. 
However, other by-products could be observed by thin layer chromatography (TLC) 
analysis. 
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Although compound 119 structure is protected in a patent application for the 
treatment of hypertension 108, to our knowledge the synthesis and structure elucidation is 
described herein for the first time. 
Structure elucidation was established by IR, 1H and 13C NMR and MS techniques. 
The IR data of these two compounds was in accordance with the performed 
molecular modifications (Table 4). The presence of alkyl groups was suggested by the 
bands appearing at 2960-2851 cm-1 (aliphatic C-H). Comparing the IR spectra of 
compounds 119 and 120 with the precursor 117, the band corresponding to hydroxyl 
group was only observed for compound 117. Additionally, the IR spectra revealed the 
presence of bands at 1639-1624 cm-1 (C=C alkene) and 3258 (C-H alkyne), in compounds 
119 and 120 spectra, respectively. 
 
Table 4 - IR data of 119 and 120. 
Group  (cm
-1
) 
119 120 
C-H (Stretch sp) ---- 3258 
C-H (Stretch sp
3
) 2960, 2924  2922, 2851 
C=O 1664 1673 
C=C (Strectch alkene) 1639, 1624 ----- 
C=C (Stretch Ar) 1593, 1511 1597, 1515 
C-H (bend sp
3
) 1418, 1362 1424, 1372 
C-O (Acyl) 1252 1272, 1247, 1225 
C-O (Alcoxy) 1164, 1134 1168, 1145, 1034, 1006 
C-H (Ar sp
2
) ----- 984, 805, 723 
C-H (Bend alkene sp
2
) 997, 969, 800 ----- 
C-H (Bend alkyne sp) ----- 682 
 
The 1H and 13C NMR data of compounds 119 and 120 are depicted in Table 5 and 
Table 6, respectively. 1H NMR spectra of both compounds (Table 5) showed signals with 
integration and multiplicities corresponding to the aromatic protons: H-2’, H-5’, and H-6’; 
the methoxyl group protons (H-3’’); the vinyl protons H-2 and H-3; and the methylic proton 
H-1’’, similarly to the precursor 117. Comparing the 1H NMR spectra of compounds 119 
and 120 with the precursor 117, the signal corresponding to a hydroxyl proton was only 
47 
 
observed for compound 117. Instead, derivatives 119 and 120 both showed a set of peaks 
characteristic of the molecular modifications performed, signals for protons H-7’, H-8’, H-
9’, H-10’ and H-7’, H-9’ for compounds 119 and 120, respectively. 
 
Table 5 - 
1
H NMR data of compounds 119 and 120. 
 
 
119 
 
 
120 
Proton* δH (values in ppm relative to Me4Si as an internal reference)** 
H-3 7.46, 1H, d, J= 16.2 7.46, 1H, d, J= 16.2 
H-6’ 7.11, 1H, d, J= 2.0 7.13, 1H, d, J=8.2 
H-2’ 7.08, 1H, s 7.09, 1H, s 
H-5’ 6.88, 1H, d, J= 8.1 7.04, 1H, d, J=8.2 
H-2 6.61, 1H, d, J= 16.2 6.62, 1H, d, J=16.2 
H-8’ 6.15-6.02, 1H, m ---- 
H-9’ 5.46-5.39, 1H, m 2.53, 1H, s 
H-10’ 5.35-5.30, 1H, m ---- 
H-7’ 4.67-4.65, 2H, dt, J= 5.4 and 1.4 4.81, 2H, s 
H-3’’ 3.92, 3H, s 3.91, 3H, s 
H-1’’ 2.38, 3H, s 2.37, 3H, s 
* Numbering of atoms was attributed for NMR assignments. Protons of the building block 117 maintained their assigned 
numbers. 
** J values are presented in Hz. 
Considering compound 119, the spectra showed a complex multiplicity of signals 
that could be explained considering the allylic coupling, a coupling between protons 
substituted on carbons α to the double bond and those on the opposite end of the double 
bond, a four-bond coupling (4J)109. The signals corresponding to the methylenic protons 
(H-7’) appear in the spectra as a doublet of triplets (dt). This pattern is the result of H-7’ 
being split by H-8’ (vicinal coupling, 3J), H-10’ (trans allylic coupling, 4J), and H-9’ (cis 
allylic coupling, 4J). In theory, this would lead to a doublet of doublets of doublets (ddd), 
but because some peaks overlap the result observed is a doublet of triplets. The signal 
corresponding to proton H-10’, considered a multiplet is actually a doublet of quartets. The 
multiplicity observed is the result of H-10’ being split by H-8’ (cis coupling, 3J), H-9’ 
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(geminal coupling, 2J), and H-7’ (allylic geminal coupling, 4J). The expected final pattern 
would be a doublet of doublet of triplets, but due to peaks overlap the spectra shows a 
doublet of quartets. The signal corresponding to proton H-9’ exhibits a similar pattern for 
the same reasons explained for proton H-10’. Assigning the two terminal vinyl hydrogens 
relies on the difference of J values for cis and trans-coupling constants. The signal 
corresponding to proton H-9’ has a wider pattern than proton H-10’ because proton H-9’ 
has a trans coupling to proton H-8’, while proton H-10’ has a lower coupling constant, 
typical of cis coupling (Figure 17). Proton H-8’ is split by H-9’ (trans coupling, 3J), H-10’ 
(cis coupling, 3J), and H-7’ (3J), which would translate in a doublet of doublet of triplets. 
However, due to overlaps, the spectra exhibits what appears to be two quintets 109. 
 
Figure 17 – Amplification of compound 119 
1
H NMR spectra peak region of protons H-7’, H-
8’, H-9’ and H-10’, with a close-up of protons H-9’ and H-10’ peaks.  
 
Regarding compound 120, the signal corresponding to the acetylenic proton (H-9’) 
was found at δH 2.53 ppm due to anisotropic shielding by the adjacent π bond. The 
methylenic protons (H-7’) on the adjacent carbon are also shielded by this anisotropic field 
of the π bond and the corresponding signals were found at δH 4.81 ppm. Allylic coupling 
was not observed in this case. 
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Table 6 - 
13
C NMR data of compounds 119 and 120. 
 
 
119 
 
 
120 
Carbon* δC (values in ppm) 
C-1 198.4 198.4 
C-4’ 150.3 149.8 
C-3’ 149.6 149.0 
C-3 143.6 143.3 
C-8’ 132.7 77.9 
C-1’ 127.5 128.5 
C-2 125.3 125.7 
C-6’ 122.8 122.5 
C-9’ 118.5 76.3 
C-5’ 112.8 113.6 
C-2’ 110.0 110.2 
C-7’ 69.7 56.6 
C-3’’ 55.9 55.9 
C-1’’ 27.4 27.4 
* Numbering of atoms was attributed for NMR assignments. Carbons of the building block 117 maintained their assigned 
numbers. 
 
13C NMR assignments for these two derivatives were determined using 
spectroscopy data tables for typical 13C chemical shifts, and by comparison with literature. 
Both compounds showed similar signals to the precursor 117, which correspond to the 
carbons of this building block moiety, and new signals related with the molecular 
modifications performed. Compound 119 exhibit three signals at: 132.7, 118.5, and 69.7 
ppm which were assigned to C-8’, C-9’, and C-7’, respectively 110. Compound 120 spectra 
also shows three peaks: 77.9, 76.3, and 56.6 ppm, assigned to C-8’, C-9’, and C-7’, 
respectively 111. 
EI-MS data for these two compounds indicated that they are both in agreement with 
the suggested structures. Compound 119 exhibits a molecular ion peak and base peak of 
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232 m/z. Compound 120 shows a molecular ion peak of 230 m/z and a base peak of 191 
m/z. 
 
 
1.3. Synthesis of glucocosamine derivative of compound 117, 
compound 121. 
The synthesis of the sugared derivative (2R,4S,5R)-5-acetamido-2-(acetoxymethyl)-
6-(2-(4-((2-methoxy-4-((E)-3-oxobut-1-en-1-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-
yl)ethoxy)tetrahydro-2H-pyran-3,4-diyl diacetate (121) was accomplished using click 
chemistry, more precisely, the Huisgen 1,3-dipolar cycloaddition. Click chemistry is the 
term used to describe reactions with a specific set of criteria: modular reactions with wide 
scope, high yields, simple reaction conditions, use of no solvent or inoffensive ones that 
can be easily removed, simple product isolation, generate armless by-products that can 
be remover by non-chromatographic methods and be stereospecific 112-113. The Huisgen 
1,3-dipolar cycloaddition, the most popular reaction of click chemistry, occurs between an 
azide and a terminal alkyne affording the 2,3-triazole moiety 113. To synthesize 121, the 
derivative 120 was added to 2-azidoethyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-
galactopyranoside using a copper (II) salt (CuSO4.5H2O) as a catalyst in the presence of 
sodium ascorbate, the reducing agent (Scheme 21) 113. Sodium ascorbate constantly 
reduced copper (II) to copper (I) maintaining significantly high levels of the catalytic 
specie.  
In this reaction, the major product formed was compound 121. Another by-product 
was formed; however, it was not isolated and identified. The major product was isolated 
by crystallization, without the need of chromatographic methods. 
 
 
Scheme 21 - Reaction conditions and results for the synthesis of compound 121 
(THF=tetrahydrofuran). 
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The IR data of compound 121 is shown in Table 7. Comparing the IR spectra of 
compound 121 with the precursor 120, the band corresponding to the bond C-H (sp) was 
only observed for compound 120, which is good indicator of the molecular modification 
occurring successfully. 1H (Table 8) and 13C NMR (Table 9) allowed to confirm the 
molecular transformations occurred. 
 
 
Table 7 – IR data of compound 121. 
Group 
 (cm
-1
) 
121 
C=O 1748 
C=C (Stretch Ar) 1667, 1596, 1513 
C-H (Bend sp
2
) 1424 
C-O (Acyl) 1371, 1165, 1140 
=C-N (Stretch) 1251 
C-O (Alcoxy) 1083, 1047 
 
 
1H NMR spectra of compound 121 shows signals with integration and multiplicities 
corresponding to the aromatic protons: H-2’, H-5’, and H-6’, as well as the methoxyl group 
(H-3’’); the vinyl protons H-2 and H-3; and the methylic protons H-1’’, similarly to the 
precursors 117 and 120. The 1H NMR spectra of compound 121 showed a set of peaks 
characteristic of the molecular modifications performed, signals for protons H-1’’’ to H-
19’’’. Since this structure is very complex and possess a large number of protons the 
assignments were made comparing with assignments described in the literature for the 
building block 2-azidoethyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-
galactopyranoside114. 
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Table 8 - 
1
H NMR data of compound 121. 
 
121 
Proton* δH (values in ppm relative to Me4Si as an internal reference)** 
H-3’’’ 7.83, 1H, s 
H-3 7.45, 1H, d, J= 16.2 
H-6’, H-2’, H-5’ 7.12-7.08, 3H, m 
H-2 6.61, 1H, d, J= 16.2 
H-11’’’ 5.54, 1H, d, J= 8.8 
H-5’’’ 5.32, 2H, dd, J= 13.1 
H-1’’’ 5.30, 1H, s 
H-4’’’ 5.15, 1H, dd, J= 13.3 and 3.2 
H-6’’’, H-7’’’ and H-8’’’ 4.65-4.55, 3H, m 
H-9’’’ 4.30-4.25, 1H, m  
H-17’’’a 4.13, 1H, d, J= 1.68 
H-17’’’b 4.11, 1H, d, J= 1.17 
H-10’’’ 4.07-4.00, 1H, m 
H-3’’ 3.89, 3H, s 
H-1’’ 2.37, 3H, s 
H-14’’’, H-16’’’, H-19’’’ 2.15 (s, 3H), 2.04 (s, 3H), 1.99 (s, 3H) 
H-12’’’ 1.85,3H, s 
* Numbering of atoms was attributed for NMR assignments. Protons of the building block 117 maintained their assigned 
numbers. 
** J values are presented in Hz. 
 
Regarding 13C NMR data, this derivative showed similar signals to the precursors 
117 and 120, spectra which correspond to the carbons of this moiety, and new signals 
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corresponding to the added molecular portion: C-1’’’ to C-19’’’ 114. Given the complexity of 
the molecular portion introduced and the large number of carbons in the molecule 
assignments were made comparing with data described in the literature for the reagent 2-
azidoethyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-galactopyranoside 114. 
 
Table 9 - 
13
C data of compound 121. 
 
121 
Carbon* δc (values in ppm) Carbon* δc (values in ppm) 
C-1 198.2 C-6’’’ 101.0 
C-11’’’ 170.7 C-10’’’  70.9 
C-13’’’ and C-15’’’ 170.4 C-8’’’ 69.8 
C-18’’’ 170.1 C-5’’’ 67.4 
C-4’ 149.9 C-9’’’ 66.1 
C-3’ 149.6 C-1’’’ 62.8 
C-3 143.2 C-17’’’ 61.4 
C-2’’’ 143.2 C-3’’ 55.9 
C-1’ 128.2 C-7’’’ 51.2 
C-2 125.7 C-4’’’ 50.2 
C-3’’’ 125.7 C-1’’ 27.4 
C-6’ 122.9 C-12’’’  23.2 
C-5’ 113.6 C-16’’’ and C-14’’’ 20.7 
C-2’ 110.3 C-19’’’ 20.6 
* Numbering of atoms was attributed for NMR assignments. Carbons of the building block 117 maintained their assigned 
numbers. 
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1.4. Synthesis of aminated derivatives of compound 117, compounds 
122 and 123 
 
The synthesis of the two aminated derivatives of compound 117, 4-(4-(2-
(diethylamino)ethoxy)-3-methoxyphenyl)but-3-en-2-one (122) and 4-(3-(((3-
(dimethylamino)propyl)(methyl)amino)methyl)-4-hydroxy-5-methoxyphenyl)but-3-en-2-one 
(123), followed different synthetic approaches. Compound 122 was obtained by a SN2 
reaction107 and compound 123 by a Mannich reaction115. In both cases, one equiv of the 
appropriate amine reacted with one equiv of compound 117 to afford the correspondent 
products. The strategy to synthesize compound 122 was similar to the previously section 
describing alkylated derivatives of compound 117. Compound 123 was synthesized 
following a protocol 115 where, primarily, the amine (N,N,N′-trimethyl-1,3-propanediamine) 
was cooled in ice bath for 5 min, then glacial acetic acid and formaldehyde were added 
dropwise. After 1h of stirring at room temperature the building block 117 was added, 
hence starting the reaction that would lead to the desirable product. Before this, another 
protocol 116 was used as an attempt to synthesize compound 123 that revealed to be 
inefficient; the starting material compound 117 and N,N,N′-trimethyl-1,3-propanediamine 
were dissolved in MeOH in the presence of formaldehyde; this mixture was under stirring 
for 45 hours (h) at 50oC. There was not a specific order of adding reagents, nor acid 
involved in the reaction, unlike the protocol described above. The acid seems to be an 
essential part for the success of this reaction; it is possible to hypothesize that the acid 
helps the production of the Mannich base to consequently react with the building block 
117. 
In these two reactions, the major products formed were compound 122 and 123. 
However, other by-products could be observed by TLC analysis. Compound 123 was 
isolated after liquid-liquid extraction followed by column chromatography; while for 
compound 122, the liquid-liquid extraction process was efficient in furnishing the desirable 
product, without the need of chromatographic methods. 
 
Scheme 22 summarizes the reaction conditions and the results obtained. 
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Scheme 22 – Reaction conditions for the synthesis of compounds 122 and 123. 
 
Structure elucidation of these two aminated derivatives 122 and 123 was 
established by IR, 1H and 13C NMR. 
 
The IR data compound 121 is showed in Table 10. Comparing the IR spectra of 
compounds 122 and 123 with the precursor 117, the band corresponding to hydroxyl 
group was only observed for compound 117 and 123, which is good indicator of the 
molecular modification occurring successfully. 1H and 13C NMR allowed to confirm the 
molecular transformations occurred (Table 11 and Table 12, respectively). 
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Table 10 – IR data of compounds 122 and 123. 
Group 
 (cm
-1
) 
122 123 
OH ------ 3500-3200 
C-H (Stretch sp
2
) 2959, 2925, 2855 2962 
C=O 1729 1633 
C=C (Stretch Ar) 1629 ----- 
C-H (bend sp
3
) 1425 1471 
C-O (Acyl) 1384, 1273 1385 
C-O (Alcoxy) 1124 1126 
C-H (bend Ar sp
2
) 669 619 
 
1H NMR spectra of compound 122 shows similar signals corresponding to the 
protons of the building block moiety: aromatic H-2’, H-5’, and H-6’; methoxyl group H-3’’; 
vinyl protons H-2 and H-3; and the methylic protons H-1’’. In contrast to compound 117 
and 123, that showed a signal corresponding to the hydroxyl group (δH ≈ 5 ppm), 
derivatives 122 shows a set of peaks characteristic of the new molecular portion 
introduced (H-7’ to H-10’). The signals of compound 122 corresponding to methylene 
protons H-7’, H-8’ and H-9’ are deshielded due to the influence of electronegative oxygen 
and nitrogen, while H-10’ are more shielded and the signals appear in the typical region of 
methyl protons. 
1H NMR spectra of compound 123 exhibits similar signals corresponding to the 
aromatic protons: H-2’ and H-6’; the protons from the methoxyl H-3’’; vinyl protons H-2 
and H-3; and the methylic protons H-1’’. The presence of only two signals integrating for 
two protons in the aromatic region highlights the molecular transformation occurred. The 
methylene protons H-7’, H-9’ and H-11’ are slightly deshielded because of the nitrogen; 
the same happends for the methylic protons H-12’. Although by TLC analysis, compound 
123 was considered to be pure, 1H NMR spectrum revealed some signals at δ1H 2.60-
2.45, 2.39-2.17, and 1.81-1.73 ppm that are considered impurities resulting from the 
amine precursor and this compound was not further investigated concerning biological 
activities. 
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Table 11 – 
1
H NMR data of compounds 122 and 123. 
 
 
122 
 
 
123 
Proton* δH (values in ppm relative to Me4Si as an internal reference)** 
H-3 7.46, 1H, d, J= 16.2 7.48, 1H, d, J= 16.05 
H-6’ 7.11, 1H, dd, J= 8.3 and 1.9 7.02, 1H, d, J= 1.7 
H-2’ 7.07, 1H, d, J= 1.9 6.84, 1H, d, J= 1.7 
H-5’ 6.91, 1H, d, J= 8.3 ----- 
H-2 6.61, 1H, d, J= 16.2 6.60, 1H, d, J= 16.05 
H-4’ ----- 5.49, 1H, brs 
H-7’ 4.24, 2H, t, J= 6.2 3.75, 2H, s 
H-3’’ 3.89, 3H, s 3.92, 3H, s 
H-8’ 3.08, 2H, t, J= 6.2 1.99, 3H, s 
H-9’ 2.81, 4H, q, J= 7.2 
2.92-2.81, 4H, m 
H-11’ ----- 
H-1’’ 2.38, 3H, s 2.36, 3H, s 
H-10’ 1.17, 6H, t, J= 7.2 1.33-1.25, 2H, m 
H-12’ ----- 2.41, 6H, s 
* Numbering of atoms was attributed for NMR assignments. Protons of the building block 117 maintained their assigned 
numbers. 
** J values are presented in Hertz (Hz). 
 
13C NMR assignments for these two derivatives were determined using 
spectroscopy data tables for typical 13C chemical shifts, and by comparison with literature. 
These derivatives showed similar signals to the precursor 117, which correspond to the 
carbons of this building block moiety, and new signals were observed corresponding to 
the molecular portion introduced. Compound 122 exhibit four new signals when 
comparing with compound 117 at δ13C: 66.4, 51.2, 47.7, and 11.0 ppm assigned to C-7’, 
C-8’, C-9’ and C-10’, respectively 117. Compound 123 showed five new signals when 
comparing with compound 117 at δ13C: 61.1, 45.4, 55.2, 24.9, and 57.1 ppm assigned to 
C-7’, C-8’/C-12’, C-9’, C-10, and C-11’, respectively 118. 
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Table 12 – 
13
C NMR data of compounds 122 and 123. 
 
 
122 
 
 
123 
Group* δC (values in ppm) 
C-1 198.4 198.3 
C-4’ 150.3 150.6 
C-3’ 149.6 148.3 
C-3 143.5 143.9 
C-1’ 127.8 125.1 
C-2 125.4 124.3 
C-6’ 122.9 123.4 
C-5’ 112.7 109.8 
C-2’ 110.1 109.7 
C-7’ 66.4 61.1 
C-3’’ 55.9 55.9 
C-8’ 51.2 
45.4 
C-12’ ----- 
C-9’ 47.7 55.2 
C-1’’ 27.4 27.0 
C-10’ 11.0 24.9 
C-11’ ----- 57.1 
* Numbering of atoms was attributed for NMR assignments. Carbons of the building block 117 maintained their assigned 
numbers. 
 
 
1.5. Synthesis of derivatives of compound 117 with carbamates and 
an ester, compounds 124, 125 and 126 
The synthesis of the three derivatives tert-butyl (2-(2-methoxy-4-(3-oxobut-1-en-1-
yl)phenoxy)ethyl)carbamate (124), tert-butyl (3-(2-methoxy-4-(3-oxobut-1-en-1-
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yl)phenoxy)propyl)carbamate (125) and methyl 2-(2-methoxy-4-(3-oxobut-1-en-1-
yl)phenoxy)acetate (126) followed a synthetic approach based on a SN2 reaction
107. The 
reaction conditions were similar to the ones described for compounds 119 and 120, one 
equivalent of 2-(boc-amino)ethyl bromide, 3-(boc-amino)propyl bromide, or methyl 2-
bromoacetate reacted with one equivalent of compound 117 to afford compound 124, 125, 
and 126, respectively. Scheme 23 summarizes the reaction conditions and the results 
obtained. The low yields can be due to the production of by-products during the reaction, 
which were not isolated and identified. These by-products could be resulting from the 
hydrolysis of the carbamates or ester groups. 
Compound 124 and 125 were purified using chromatographic methods while 
compound 126 was purified by extraction. 
 
 
Scheme 23 – Reaction conditions for the synthesis of compounds 124, 125, and 126. 
 
Structure elucidation of these three aminated derivatives was established by IR, 1H 
and 13C NMR. GC-MS analysis was also performed for the two amides, compounds 124 
and 125. 
The IR data of these three compounds is shown in Table 13. The presence of bands 
between 3100-3500 cm-1, typical of the secondary amines N-H bond (compounds 124 and 
125), could indicate the presence of the desirable compounds; however, this band 
overlapped with the typical hydroxyl group band and further spectroscopic techniques 
were used to better characterize these structures. Regarding compound 126, comparing 
the IR spectra of this compound with the precursor 117, the band corresponding to 
hydroxyl group was only observed for compound 117 which is good indicator of the 
molecular modification occurring successfully. 
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Table 13 – IR data of compounds 124, 125, and 126. 
Group  (cm
-1
) 
124 125 126 
N-H (stretch) 3447 3377 ----- 
C-H (Stretch sp
3
) 2920, 2852 ----- 2918, 2849 
C=O 1636 1686 1733 
N-H (bend) ----- 1669, 1644 ----- 
C=C (Stretch Ar) ----- 1621, 1595, 1518 1634, 1515, 1463 
C-O (Acyl) 1385 1273, 1260, 1225 1262 
C-O (Alcoxy) 1099 1167, 1138, 1033 1111 
C-H (bend Ar sp
2
) 668 975 668 
 
 
 
1H and 13C NMR data of compounds 124, 125, and 126 are depicted in Table 14 and 
Table 15, respectively. 1H NMR spectra of all three compounds show similar signals 
corresponding to the building block 117 moiety protons: aromatic H-2’, H-5’, and H-6’; 
methoxyl group H-3’’; vinyl protons H-2 and H-3; and the methylic protons H-1’’ Instead of 
the signal corresponding to the hydroxyl group, the derivatives 124, 125, and 126 show a 
set of peaks characteristic of the new molecular portion introduced. The methylene/methyl 
protons H-7’ and H-8’ for compound 124, H-7’ and H-9’ for compound 125, and H-7’ and 
H-9’ for compound 126 are deshielded due to the electronegativity of the oxygen and 
nitrogen and the corresponding signals appeared between 2 and 5 ppm. The signal 
corresponding to the proton of the secondary amine only appears in compound 125 
spectrum, the absence of this signal in compound 124 could be due to chemical exchange 
of the -NH proton, that causes the signal to be very broad and weak. 
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Table 14 - 
1
H NMR data of compounds 124, 125, and 126.
 
 
124 
 
125 
 
126 
Proton* δH (values in ppm relative to Me4Si as an internal reference)** 
H-3 7.45, 1H, d, J= 16.2 7.46, 1H, d, J= 16.2 7.45, 1H, d, J= 16.2 
H-6’ 7.10, 1H, dd, J= 8.1 and 
1.8 
7.11, 1H, d, J= 8.2 
7.09, 2H, dd, J= 6.7 and 
1.9 
H-2’ 7.06, 1H, d, J= 1.8 7.07, 1H, s 
H-5’ 6.94, 1H, d, J=8.1 6.86, 1H, d, J= 8.2 6.80, 1H, d, J= 6.7 
H-2 6.59, 1H, d, J= 16.2 6.61, 1H, d, J= 16.2 6.61, 1H, d, J= 16.2 
H-7’ 4.91, 2H, m 4.14, 2H, t, J= 5.0 4.76, 2H, s 
H-8’ 3.23-3.18, 2H, m 2.04, 2H, t, J= 5.0 ----- 
H-9’ ----- 3.38, 2H, d, J= 5.0 3.81, 3H, s  
H-3’’ 3.94, 3H, s 3.92, 3H, s 3.93, 3H, s 
H-1’’ 2.37, 3H, s 2.38, 3H,  2.38, 3H, s 
H-10’ 2.17, 9H, s 5.50, 1H, brs ----- 
H-11’ ----- 1.46, 9H, s ----- 
* Numbering of atoms was attributed for NMR assignments. Protons of the building block 117 maintained their assigned 
numbers. 
** J values are presented in Hz. 
 
13C NMR assignments for these three derivatives were determined using 
spectroscopy data tables for typical 13C chemical shifts, and by comparison with literature. 
This derivative showed similar signals to the precursor 117, which correspond to the 
carbons of this building block moiety, and new signals of the molecular portion added. 
Compound 123 exhibit five carbons peaks at δ 13C: 68.2, 42.3, 160.5, 77.3, and 29.7 ppm 
assigned to C-7’ to C-11’, respectively 119. Compound 124 shows six carbons peaks at δ 
13C: 68.2, 30.9, 38.9, 156.1, 79.0, and 28.5 ppm assigned to C-7’ to C-12, respectively 119. 
Compound 126 exhibits three carbon peaks at δ 13C: 66.0, 169.0, and 52.4 ppm, 
corresponding to C-7’ to C-9’, respectively 120. 
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Table 15 - 
13
C NMR data of compounds 124, 125, and 126. 
 
124 
 
125 
 
 
126 
Group* δC (values in ppm) 
C-1 198.5 198.4 198.4 
C-9’ 160.5 38.9 52.4 
C-4’ 148.2 150.5 149.7 
C-3’ 146.9 149.5 149.3 
C-3 143.8 143.5 143.2 
C-1’ 127.0 127.6 128.8 
C-2 125.0 125.3 125.5 
C-6’ 123.6 122.9 122.5 
C-5’ 114.8 112.2 113.4 
C-2’ 109.3 109.7 110.5 
C-7’ 68.2 68.2 66.0 
C-10’ 77.3 156.1 ----- 
C-8’ 42.3 30.9 169.0 
C-3’’ 56.0 55.8 56.0 
C-11’ 29.7 79.0 ----- 
C-1’’ 27.3 27.4 27.4 
C-12’ ----- 28.5 ----- 
* Numbering of atoms was attributed for NMR assignments. Carbons of the building block 117 maintained their assigned 
numbers. 
 
Compounds 124 and 125 were analyzed GC-MS. MS data for these two compounds 
indicated that MS spectra are both in agreement with the suggested structures. 
Compound 124 exhibits a molecular ion peak of 334.8 m/z and base peak of 281.9 m/z. 
Compound 125 shows a molecular ion peak and base peak of 349.1 m/z. 
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1.6. Other synthetic attempts that were ineffective in obtaining 
curcumin derivatives 
 
Throughout the development of the experimental work performed in this thesis other 
compounds were attempt to be synthesized, in order to increase the library of curcumin 
derivatives and for SAR studies. Although the target compounds were not isolated from 
the reaction conditions depicted in Table 16 and Table 17, these are listed to discuss 
some of the attempts and strategies used. Reagents, reaction conditions and desirable 
products of these attempts are depicted in Table 16 and Table 17. 
 
 
Table 16 - Reaction conditions for the synthesis of curcumin derivatives using SN2 
reaction (entry 1 and 2) and the Claisen-Schmidt condensation (entry 3). 
Reaction 
n.º 
Reagents 
Reaction 
conditions 
Target molecule 
1 
 
 
Acetone, 
Cs2CO3. 
MW 200W, 
3h at 65
o
C 
107
 
 
 
 
2 
 
 
 
 
3 
 
 
EtOH, 4
o
C, 
40% KOH. 
28 h at r.t. 
69
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Table 17 - Reaction conditions for the synthesis of derivatives of compound 117 using 
Ullmann’s reaction (entry 1-5). 
Entry Reagents 
Reaction 
conditions 
Target molecule 
1 
 
 
MeOH, 
K2CO3, CuI, 
N, N- 
dimethylglyci
ne, 110
o
C, 2 
days.* 
 
 
2 
 
 
 
 
3 
 
 
 
 
4 
 
 
 
 
5 
 
 
 
 
* Ullmann’s reaction conditions were investigated previously with another scaffold in the group (unpublished 
results). 
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Entry 1 and 2 of Table 16 followed a SN2 approach, similar to the ones described for 
previous compounds (119, 120, 122, 124, 125, and 126), with the aim of producing the 
corresponding curcumin derivatives. In these reactions, the building block curcumin (1) 
was mixed with the appropriate amine or alkyne bromide and let to react in alkaline 
conditions. After work up, the major product was isolated and analyzed by 1H and 13C 
NMR spectroscopy. The results led to the conclusion that the isolated compounds were 
not the desirable compounds and no further investigations were performed. Alkaline 
conditions were hypothesized to degrade curcumin, which could have been the main 
reason for this outcome. The target molecule of entry 2 of Table 16 has already been 
described as possessing antiviral activity 121, hence our aim to synthesize and test this 
compound in order to evaluate the cytotoxicity and P-gp inhibition. 
In entry 3 of Table 16 had the aim of producing a third building block and curcumin 
derivative. Similarly to compounds 117 and 33, a Claisen-Schmidt condensation was the 
synthetic strategy; after work-up, the isolated compound was analyzed by 1H and 13C 
NMR and since the spectra indicated that the isolated compound was not the desirable 
product no further investigations were performed. 
Entry 1 to 5 of Table 17 followed a different synthetic strategy from the previous 
ones, the Ullmann’s reaction. All the major products formed in the reaction were isolated 
using chromatographic methods and analyzed by 1H and 13C NMR. The spectra indicated 
that the isolated compound were not the desirable product and no further investigations 
were performed. 
 
 
2. Stability and photostability studies 
 
Under neutral and basic pH conditions, curcumin (1) is very unstable, and eventually 
is degraded to ferulic acid and feruloylmethane, as depicted in Scheme 244, 94. Such 
instability is associated with the methylene moiety between the two carbonyl groups: the 
hydrogens of the methylene group are very acidic making this molecule only stable at 
acidic pH. Curcumin (1) is hydrophobic; therefore, it is soluble in organic solvents such as 
dimethyl sulfoxide (DMSO), MeOH, EtOH or acetone and poorly soluble in aqueous 
solvents 4. Curcumin (1) in phosphate buffer at pH 7.2 is rapidly and almost completely 
degraded (approximately 90%, within 30 minutes). Degradation of curcumin (1) is 
extremely slow at pH 1 to 6. Vanillin, ferulic acid, feruloylmethane (117) and trans-6-(4’-
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hydroxy-3’-methoxyphenyl)-2,4-dioxo-5-hexenal are degradation products of curcumin (1) 
4. Besides being prone to hydrolysis under alkaline conditions, curcumin (1) is also very 
susceptible to photochemical degradation 94. 
 
 
Scheme 24 - Hydrolytic degradation of curcumin (1). 
 
Given these curcumin (1) characteristics, were tested and compared the other two 
building blocks synthesized 117 and 33 to evaluate if they are more, less or as stable as 
curcumin (1). 
 
 
2.1. Stability studies 
 
Stability studies concerning different pH, solvents, temperature and storage time 
were performed by high-performance liquid chromatography (HPLC) and aimed to 
evaluate compounds stability in a quantitative manner, thus examining if compounds 117 
and 33 are more, less or as stable as curcumin. Stability studies were divided in different 
assays each one with a different purpose: a pH stability assay, a biological buffer assay 
and temperature/storage time assay. The stability was evaluated comparing the 
challenged samples with the standard compounds dissolved in DMSO, immediately 
injected at room temperature. The curcumin (1) used was purchased, and according to 
our study showed a purity level of 55% (information provided by the seller company 
describes 65% purity by HPLC analysis). Compounds 117 and 33 used for these assays 
were the compounds isolated after the described purification procedures, which showed 
96% and 72% purity in HPLC analysis, respectively. Figure 18 shows curcumin (1), 
compound 117 and 33 chromatograms in the chromatographic system analyzed. 
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Figure 18 – Representative HPLC chromatogram of (A) curcumin (1), (B) compound 117 
and  (C) 33 [=254 nm, C18, isocratic solution of MeOH:H2O:acetic acid (70:30:1)]. HPLC 
chromatogram of curcumin (1): bisdemethoxycurcumin (3, k= 0.29), desmethoxycurcumin (2, k= 
0.46) and curcumin (1, k=0.58) 
122
. HPLC chromatogram of compound 117 (k=0.05). HPLC 
chromatogram of compound 33 (k= 0.14). 
 
At 254nm it is possible to observe a second major peak in all chromatograms with a 
retention time of 3.36-3.38 min; this peak can be assigned to DMSO which also absorb at 
254 nm (data not shown). In curcumin (1) chromatogram three peaks were observed that 
were attributed to: bisdemethoxycurcumin (3, k= 0.29), desmethoxycurcumin (2, k= 0.46) 
and curcumin (1, k=0.58) as described in the literature 122. Commercialized curcumin (1) 
contains small amounts of other curcuminoids, hence the presence of more than one 
peak.  
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2.1.1. pH Stability assay 
 
Five pH values were selected and obtained with following buffers: HCl pH 1.0, 
sodium acetate pH 5.0, potassium phosphate pH 6.7, phosphate buffered saline (PBS) pH 
7.4 and sodium boric acid pH 9.1. The compounds were dissolved in each buffer, to the 
final concentration of 10-4 M, and let to incubate overnight at room temperature, except in 
HCl buffer that incubated only for 75 min 123. 
After overnight incubation the compounds in certain buffers precipitated: curcumin 
(1) precipitated in all buffers; compound 117 precipitated in all buffers; compound 33 at pH 
1, 6.7 and 7.4. The precipitate was filtrated and both filtrated and solid (dissolved in 
MeOH) were analyzed separately.  
Figure 19 and Figure 20 shows curcumin (1) filtrate solution chromatogram after 
being subjected to pH 9.1 and curcumin (1) precipitate overlapped chromatograms after 
being subjected to different buffers, respectively. 
The filtrate solution of curcumin (1) corresponded solely to buffer solution (data not 
shown). It was hypothesized that all curcumin (1) precipitated at lower pH values (pH 1, 
pH 5, pH 6.7 and 7.4) because this compound would be in a non-ionized form and, thus, 
not soluble in aqueous solvents; at the highest pH value (pH 9.1) curcumin (1) could have 
been degraded; the chromatogram depicted in Figure 19 is very different from the 
standard one; furthermore, the spectra of each peak showed no similarities with curcumin 
(1) UV spectra. These peaks could be due to degradation products as it would be 
expected since curcumin (1) degrades in alkaline conditions. 
The precipitate formed after curcumin (1) incubation with certain buffers was 
dissolved and analyzed. As suspected, buffers with lower pH values (pH 1, 5, 6.7 and 7.4) 
are associated to the non-ionized form and thus the compound precipitate in aqueous 
solvents. From pH 1 to 7.4 (Figure 20), the main peak (k= 0.66) corresponds to curcumin. 
At pH 9.1 (Figure 19) is observed a different compound, possibly the same as the one 
present in chromatogram shown in Figure 19. The proportion of the area correspondent to 
curcumin (1) peak maintained around 55% (with small oscillations), except for pH 7.4 in 
which the area decreased to 49%. 
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Figure 19 - Curcumin (1) filtrate solution chromatogram after being subjected to sodium 
boric acid (pH 9.1) and respective retention factor of each peak [=399 nm, C18, isocratic solution 
of MeOH:H2O:acetic acid (70:30:1)]. 
 
 
Figure 20 – Curcumin (1) precipitate overlapped chromatograms after being subjected to 
different buffers [=399 nm, C18, isocratic solution of MeOH:H2O:acetic acid (70:30:1)]. 
 
Figure 21 depict compound 117 filtrate overlapped chromatograms after being 
subjected to different buffers. It is possible to observe that in the chromatograms for 
higher pH values (pH 6.7, 7.4, and 9.1) besides compound 117 another peak is present. 
This second peak could be due to some compound 117 degradation, caused by alkaline 
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conditions. The spectra of second peak showed no similarities with compound 117 UV 
spectra. 
The precipitate chromatograms of compound 117 corresponded solely to buffer 
solution (data not shown). The proportion of the area correspondent to compound 117 
peak maintained around 96% (with small oscillations), except for pH 9.1 in which the area 
decreased to 55%. 
 
 
Figure 21 - Compound 117 filtrate overlapped chromatograms after being subjected to 
different buffers [=399 nm, C18, isocratic solution of MeOH:H2O:acetic acid (70:30:1)]. 
 
Figure 22 and Figure 23 shows compound 33 filtrate solution overlapped 
chromatograms after being subjected to different buffers and compound 33 precipitate 
overlapped chromatograms after being subjected to different buffers, respectively. 
Compound 33 solution maintained the same composition regardless the buffer. From this 
result it was hypothesized that this compound under different pH conditions can be the 
most stable of the three. 
In Figure 23, compound 33 chromatograms exhibited a main peak with a retention 
factor of 0.18 that corresponds to the indicated compound. No considerable differences 
can be observed between this and the standard chromatogram. The proportion of the area 
correspondent to compound 33 peak maintained around 72% (with small oscillations) in 
both filtrate solution and precipitate chromatograms. 
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Figure 22 - Compound 33 filtrate solution overlapped chromatograms after being subjected 
to different buffers [=399 nm, C18, isocratic solution of MeOH:H2O:acetic acid (70:30:1)]. 
 
 
Figure 23 - Compound 33 precipitate overlapped chromatograms after being subjected to 
different buffers [=399 nm, C18, isocratic solution of MeOH:H2O:acetic acid (70:30:1)]. 
 
By chromatograms analysis of the three compounds subjected to different buffers 
we can hypothesize that compound 33 is the most stable compounds, followed by 
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compound 117 and then curcumin (1), which exhibited the most prominent degradation in 
alkaline conditions. 
 
 
2.1.2. Biological buffer assay 
 
The biological buffer assay was selected to evaluate if the compounds showed 
significant degradation in the cell medium used for cell culture (see biological reagents). It 
is of great importance that the compounds maintain stable in this buffer in order to reach 
the cells as intact molecules, not as degradation products. The compounds were 
incubated for 5, 10, 20 and 30 min at 37oC in biological buffer, having a final concentration 
of 1.5×10-3M, the solution were filtrated and injected. Figure 24, Figure 25 and Figure 26 
exhibit curcumin (1), compound 117 and 33 overlapped chromatograms when subjected 
to biological buffer in the specified condition. 
Curcumin (1) overlapped chromatograms show that the retention factor of the main 
peak are not exactly the same (k ≈ 0.55—0.70). Nevertheless, the two main peaks 
observed have overlapping UV-Vis spectra and they were hypothesized to correspond 
both to curcumin (1). The same was observed for compounds 117 (k ≈ 0.26-0.37) and 33 
(k ≈ 0.34-0.46), respectively. The presence of two distinct peaks can be due to the pKa of 
the compound being similar to the pH of the biological buffer, which can be translated into 
a protonated and deprotonated form of the same compound in the sample. 
 
 
Figure 24 - Curcumin (1) overlapped chromatograms when subjected to biological buffer for 
5, 10, 20 and 30 min at 37
o
C [=399 nm, C18, isocratic solution of MeOH:H2O:acetic acid 
(70:30:1)]. 
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Figure 25 - Compound 117 overlapped chromatograms when subjected to biological buffer 
for 5, 10, 20 and 30 min at 37
o
C [=399 nm, C18, isocratic solution of MeOH:H2O:acetic acid 
(70:30:1)]. 
 
Figure 26 – Compound 33 overlapped chromatograms when subjected to biological buffer 
for 5, 10, 20 and 30 min at 37
o
C [=399 nm, C18, isocratic solution of MeOH:H2O:acetic acid 
(70:30:1)]. 
 
When comparing with the standard solutions the compounds exhibited a similar 
behavior in the biological buffer and appear to be chemically stable at these conditions. 
Hence, the biological buffer does not degrade these compounds (1, 33, and 117). 
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2.1.3. Temperature/storage time assay 
 
The temperature/storage time assay was performed in order to evaluate if the 
compounds would maintain their stability with different temperatures conditions and 
storage times. The compounds were dissolved in DMSO, having a final concentration of 
10-4M, and store at -20oC, 4oC and room temperature for 6, 15, and 21 days 123. After 
being subjected to such conditions the stability was evaluated by HPLC. Figure 27, Figure 
28, and Figure 29 exhibit curcumin (1), compound 117 and 33 overlapped chromatograms 
when subjected to -20oC, 4oC and r.t. along 6, 15, and 21 days, respectively. 
 
Curcumin (1) chromatograms indicate that this compound degraded with all 
temperatures along all storage days defined. Between 3-4.6 min of the chromatographic 
run the degradation products are visible and around 5-6 min other curcuminoids, or 
degradation products are observed with similar UV-Vis spectra. 
The proportion of the area correspondent to curcumin/curcuminoids peak gradually 
decreased with increased storage time from 54% (with small oscillations) to 28%. 
However, the proportion of the area correspondent to curcumin/curcuminoids peak was 
similar between temperatures with the same storage time. 
 
 
 
Figure 27 - Curcumin (1) overlapped chromatograms when subjected to -20
o
C, 4
o
C and r.t. 
along (A) 6 days, (B) 15 days, and (C) 21 days [=399 nm, C18, isocratic solution of 
MeOH:H2O:acetic acid (70:30:1)]. 
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Compound 117 also degraded with all temperatures along all storage days defined. 
Between 3.45-3.65 min of the chromatographic run compound 117 or a degradation 
product with similar UV-Vis spectra are observed, and peaks with higher retention time 
are degradation products. Two possible degradation products are observed after 6 days, 
and three possible degradation products after 15 and 21 days. The proportion of the area 
correspondent to compound 117 peak gradually decreased with increased storage time 
from 94% (with small oscillations) to 34%. However, the proportion of the area 
correspondent to compound 117 peak was similar between temperatures with the same 
storage time. 
 
 
 
Figure 28 - Compound 117 overlapped chromatograms when subjected to -20
o
C, 4
o
C and 
r.t. over (A) 6 days, (B) 15 days, and (C) 21 days [=399 nm, C18, isocratic solution of 
MeOH:H2O:acetic acid (70:30:1)]. 
 
Regarding compound 33, after 6 days storage the chromatograms exhibit the 
presence of this compound between 3.86-3.88 min and impurities with lower retention 
time. At 15 days two peaks could be attributed to compound 33 or a degradation product 
with similar UV-Vis spectra, between 3.70-4min of the chromatographic run. Peaks with 
lower retention time are due to degradation products. After 21 days storage, compound 33 
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was degraded or is present in vestigial amounts, and only degradation products are 
observed.  
The proportion of the area correspondent to compound 33 peak gradually 
decreased with increased storage time from 56% (with small oscillations) to 36%. 
However, the proportion of the area correspondent to compound 33 peak was similar 
between temperatures with the same storage time. 
 
 
Figure 29 - Compound 33 overlapped chromatograms when subjected to -20
o
C, 4
o
C and r.t. 
over (A) 6 days, (B) 15 days, and (C) 21 days [=399 nm, C18, isocratic solution of 
MeOH:H2O:acetic acid (70:30:1)]. 
 
In this assay, it was possible to observe two peaks for each compound, which could 
be due to the protonation form of the compounds or could be degradation products 
(intermediates for other degradation products) with identical spectra to the parent 
compound curcumin (1), 117 or 33. Temperature variations seem to not influence 
significantly the stability. All compounds have shown to be unstable along the temperature 
and storage times tested. Curcumin (1) and compound 117 may have similar stability, 
after 6 days of storage they already show degradation signals. Compound 33 was proving 
to be the most stable, but at 21 days of storage the compound had completely 
decomposed. 
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2.2. Photostability studies 
 
The photostability studies aimed to analyze compounds stability in a qualitative 
manner, thus examining the compounds degradation. Photostability studies of curcumin 
(1), compound 117, and 33 methanolic solutions were accomplished using UV-Vis 
spectrophotometry. The solutions were subjected to selected times intervals of light 
exposure: 30 min, 1 h, 2 h, 3 h and 24 h, and compared to a standard solution, 0 min of 
light exposure of the respective compound. UV-Vis spectra of each standard solution are 
shown in Figure 30 and revealed the spectral differences between compounds in 
maximum absorption wavelength and intensity of absorption. Curcumin (1) standard 
solution shows three maximum absorption wavelengths at 424, 258, and 207 nm with the 
respective molar attenuation coefficient (ε) of 17400, 4800, and 10900 M-1·cm-1. 
Compound 117 standard solution shows four maximum absorption wavelengths at 399, 
243, 222, and 205 nm and ε of. 11400, 5700, 4900, and 6000 M-1·cm-1, respectively. 
Compound 33 standard solution shows four maximum absorption wavelengths at 387, 
368, 264, and 208 nm with the respective ε of 11100, 10000, 6000, and 12800 M-1·cm-1. 
To evaluate compounds susceptibility to photodegradation is essential to analyze 
bathochromic or hypsochromic shifts as well as hyperchromic and hypochromic effects on 
UV-Vis spectra of light exposed solution 94. The bands observed for the three compounds 
at 205-208 nm could indicate n→σ* transitions, which is usually associated with alcohols. 
The conjugated ketone π system of the three compounds appear in bands at higher 
wavelengths than 300 nm due to the n→π* transitions, and around 250nm due to π→π* 
transitions. The bands at 424 and 399 nm, of curcumin (1) and compound 33 respectively, 
could be attributed to the aromatic chromophore conjugated with the double bond and 
carbonyl group of each compound 124. 
 
 
Figure 30 – UV-Vis spectra of standard solutions at 10
-4
M concentration of curcumin (1), 
compound 117 and compound 33 (t= 0 min). 
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Curcumin (1) UV-Vis spectra regarding different light exposure times are depicted in 
Figure 31. All the light exposed and protected solutions had shown no considerable 
bathochromic or hypsochromic shifts when compared to the standard solution. The 30 min 
light exposed solution show a generalized hypochromic effect (Figure 31 A); consecutive 
light exposed solutions show a hyperchromic effect regarding 424 nm maximum 
absorption and an hypochromic effect regarding 258 and 207 nm maximum absorption. 
After 24h of light exposure (Figure 31 B) the solution shows a generalized hypochromic 
effect in all maximum absorption wavelengths.  
A previously described study indicated that curcumin (1) is more photostable than 
the curcuminoid BDMC (3) in MeOH solution 94. However, when curcumin (1) is in a 
cyclodextrin solution shows lower photostability and the curcuminoid BDMC (3) shows 
higher photostability 94. 
A control solution protected from light exposure revealed no significant changes in 
the UV-Vis spectra when compared to the standard solution (data not shown). 
 
 
 
Figure 31 – A) UV-Vis spectra of curcumin (1) after different light exposure times, from 0 min 
(standard) to 3h; B) UV-Vis spectra of curcumin (1) after 24h light exposure and standard solution. 
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Compound 117 UV-Vis spectra regarding different light exposure times are depicted 
in Figure 32. All the light exposed and protected solutions (controls not shown) had shown 
no considerable bathochromic or hypsochromic shifts when compared to the standard 
solution. Consecutive light exposed solutions show a hyperchromic effect throughout the 
spectra, which is still observed after 24 h of light exposure in all maximum absorption 
wavelengths compared with both compound 117 UV-Vis at 0 min and the corresponding 
protected control solutions. 
 
 
Figure 32 - UV-Vis spectra of compound 117 after different light exposure times, from 0 min 
(standard) to 24h.  
 
Comparing to curcumin (1), it is possible to conclude that UV-Vis spectra of 
compound 117 are affected by light exposure but no significant hipso or bathochromic 
effects were observe. Nevertheless, after 24 h the alteration of compound 117 spectra 
revealed an increase in ε (when compared to standard solution) contrary to curcumin (1) 
that gave a decrease of ε. 
 
Compound 33 UV-Vis spectra regarding different light exposure times are depicted 
in Figure 33. All the light exposed and protected solutions had shown no considerable 
bathochromic or hypsochromic shifts when compared to the standard solution. The 
standard solution, 30 min and 1 h light exposure solution shows overlapping spectra; 2 
and 3 h light exposed solutions show a hyperchromic effect regarding 424 nm maximum 
absorption and an hypochromic effect regarding 258 and 207 nm maximum absorption. 
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After 24 h of light exposure the solution shows a generalized hypochromic effect in all 
maximum absorption wavelengths. 
 
 
 
Figure 33 – A) UV-Vis spectra of compound 33 after different light exposure times, from 0 
min (standard) to 3h; B) UV-Vis spectra of compound 33 after 24h light exposure and standard 
solution. 
 
When comparing compound 33 with curcumin (1) it is possible to conclude that both 
UV-Vis spectra are affected by light exposure but no significant hipso or bathochromic 
effects were observe. After 24 h the alteration of compound 33 spectra revealed a 
decrease in ε similarly to curcumin (1). 
 
After this UV-Vis spectra analysis it is not possible to conclude that compounds 117 
and 33 are more or less stable than curcumin, all compounds spectra show differences 
from the standard solution after light exposure which could be due to some degradation. 
The fact that some curcumin (1) and compound 33 shows hyperchromic effect after 3 h of 
light exposure and hypochromic effect after 24h could mean that over 3h the compounds 
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degraded losing their chromophores, and from 3 to 24 h the degradation product also 
suffered degradation. 
 
 
3.  Biological activity studies  
 
 
The synthesized compounds 117, 119, 120, 121, and 125 and curcumin (1) were 
tested in order to evaluate their cytotoxicity and P-gp inhibition. The compounds were 
tested by Vanessa Rodrigues as part of her PhD work. The tests were conducted at the 
Institute of Molecular Pathology and Immunology at the University of Porto – IPATIMUP. 
The compounds cytotoxicity was evaluated with an indirect method, the 
sulforhodamine B colorimetric assay (SRB assay). This assay is based in cell density 
determination, evaluated by the measurement of cellular protein content 125. The cell lines 
used for this assay were NCI-H460 (lung carcinoma cells). The tested tumor cell growth 
inhibitory activity of the compounds was compared to doxorubicin. 
In the drug sensitive cell line, doxorubicin exhibited the lowest half maximal 
inhibition of cell growth (GI50) value followed by curcumin; none of the derivatives showed 
GI50 values lower than curcumin (1) or doxorubicin. Among the synthesized derivatives, 
compounds 119 and 120 were the most potent tumor cell growth inhibitors in the cell line 
NCI-H460. Compounds 125, 117, and 121 showed sequentially higher GI50 values. 
The detection of P-gp activity was accomplished using the rhodamine 123 assay 126. 
This method is based on the fluorescent properties of rhodamine 123 and P-gp’s ability to 
efflux this compound. Hence, by flow cytometry it is possible to detect and quantify 
rhodamine 123 inside the cells 126. In this assay, the K562 cells (a chronic myeloid 
leukemia cell line) and K562-Dox cells (P-gp overexpressing cells derived from K562 cell 
line) were used. The tested compounds were compared with verapamil, a known P-gp 
inhibitor. 
Curcumin (1) showed the lowest P-gp inhibitory activity. Verapamil was the most 
potent compound regarding P-gp inhibition, followed by compound 125 and 119. 
Compounds 121, 117, and 120 exhibited sequentially lower P-gp inhibition. However, the 
latter three compounds inhibition is almost null. 
Compounds 119 and 125 may act as dual ligands, since they show tumor cell 
growth inhibition and P-gp inhibitory activity, exhibiting a synergistic effect. 
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Considering these results, it is possible to hypothesize about some SAR features. 
Regarding tumor cell growth inhibition curcumin (1) and 117 both possess the same 
substitution pattern in the aromatic rings in contrast to compounds 119, 120, 121 and 125, 
so the hydroxyl group may not be essential for this biological activity. The methoxyl group 
was maintained in every tested compounds, thus it is not possible to conclude about the 
importance of this substituent on the aromatic rings. Curcumin (1) showed to be more 
potent than compound 117, which means that the presence of two aromatic rings may 
confer higher potency (since smaller linkers have already been proven to be beneficial for 
tumor cell growth inhibition 80). Compounds 119, 120 and 125 were the most potent tumor 
cell growth inhibitors when compared to the other derivatives of compound 117 in both cell 
lines, which could indicate that the strong electron density, confer by π electrons of the 
double and triple bond, and the moderate electron density, confer by the nonbonding pair 
of electrons of the nitrogen, may favor this activity. Studies with more derivatives are 
needed to corroborate these hypothesis. 
Considering the P-gp inhibitory activity, compounds 125 and 119 were the most 
potent inhibitors when compared to the other derivatives of compound 117. Again the 
nonbonding pair of electrons of the nitrogen and the π electrons of the double bond could 
be important to inhibit P-gp. Interestingly, compound 120 was not a good P-gp inhibitor 
despite the similarity to compound 119. More studies with new derivatives and the 
synthesized derivative 33, 122, 123, 124, and 125 should provide more information to 
establish the SAR. 
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CHAPTER III: 
CONCLUSION
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CONCLUSIONS 
 
 
Nature provides a large variety of molecules, with different degrees of complexity 
and many biological activities. Curcumin (1) is an example of such molecules, which has 
been associated with several interesting biological activities. 
However, the extensive metabolism and instability prevent curcumin (1) from being 
used at its full potential. As mentioned before, we aimed to synthesize building blocks 
potentially more stable than curcumin, and several derivatives derived from one of the 
building blocks. We were able to synthesize successfully two out of three building blocks 
and eight out of sixteen derivatives.  
The synthesized building blocks were not the originally planned target molecules. 
Nevertheless, the enone (117) and dienone (33) building blocks are curcumin derivatives 
without the base sensitive methylene moiety and the synthesis of derivatives proceeded. 
Due to the satisfactory yield and the convenient purification obtained for compound 117 
eight derivatives were synthesized from 117, possessing different substitution patterns in 
the phenolic group. Ten derivatives were synthesized and seven are herein being 
described for the first time. Structure elucidation was accomplished on the basis of several 
spectrophotometric and non-spectrophotometric techniques. 
In order to evaluate the chemical and photostability of the building blocks when 
compared to curcumin (1) four assays were prepared. Regarding the pH buffers assay it 
can be hypothesized that compound 33 is the most stable compound, followed by 
compound 117. Curcumin (1) showed to be most unstable of the three compounds. The 
biological buffer assay has shown that this medium did not degrade any of the 
compounds. The temperature/storage time assay showed that all of the tested 
compounds are unstable along the temperature and storage times tested. Curcumin (1) 
and compound 117 exhibited similar stability; and compound 33 has proven to be the 
most unstable in the described conditions. 
Another aim of this thesis was to evaluate the ability of curcumin derivatives to 
inhibit tumor cell growth and P-gp activity. Compounds 119 and 125 showed the highest 
potency in both assays when compared to the other synthesized derivatives (117, 120, 
and 121). However, curcumin (1) was the most potent tumor cell growth inhibitor in 
sensitive cancer cell lines, when compared to its derivatives. On the basis of the 
performed biological assays it is possible to draw some conclusion and establish a SAR. 
Regarding tumor cell growth inhibition the hydroxyl group may not be essential for this 
biological activity; the presence of two aromatic rings may confer higher potency; high 
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electron density on the phenolic group substituents may favor this activity. The high 
electron density on the phenolic group substituents may also be important to inhibit P-gp. 
Studies with more derivatives are needed to corroborate these hypotheses. 
Future studies can be proposed in order to continue and improve the present work. 
It would be interesting to introduce the same substitution patterns used in derivatives of 
compound 117 in curcumin (1) and compound 33; and test the derivatives for the 
possibles tumor cell growth and P-gp inhibitory activities. Hence, a more accurate SAR 
could be established. It would also be interesting to synthesize derivatives of compound 
124 and 125 without the protecting group (boc) and allowing the hydrolysis of the 
carbamates, and consequent evaluation of the biological activity of the resulting carbamic 
acids. 
Overall, the aims of this thesis were accomplished. 
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CHAPTER IV: 
MATERIALS AND METHODS 
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1. General Methods 
 
All reagents and solvents were purchased from Sigma Aldrich, and had no further 
purification process, except for 2-bromo-N,N-diethylethan-1-amine hydrobromide that was 
submitted to liquid extraction (NaOH, CH2Cl2) to be in the non-ionized form. Solvents were 
evaporated using rotary evaporator under reduced pressure, Buchi Waterchath B-480. All 
reactions were monitored by TLC carried out on precoated plates with 0.2 mm of 
thickness using Merck silica gel 60 (GF254). The visualization of the chromatograms was 
under UV light at 254 and 365 nm. Microwave (MW) reactions were performed in 
glassware open vessel reactors in a MicroSYNTH 1600 Microwave Labstation from 
Millestone (ThermoUnicam, Portugal). The internal reaction temperature was controlled by 
a fiber-optic probe sensor. Purification of the synthesized compounds was performed by 
chromatography flash and semi-flash columns using Merck silica gel 60 (0.040-0.063 mm 
and 0.063-0.200 mm, respectively), chromatography flash cartridge (GraceResolv®, 
Grace Company, Deerfield, IL, USA), Discovery® DSC-SAX SPE anionic exchange 
cartridge , and preparative thin layer chromatography using Merck silica gel HPLC60 RP-
18 (GF254) plates purchased from Merck (Germany). Melting points (mp) were measured 
in a Köfler microscope and are uncorrected. Infrared (IR) spectra were obtained in KBr 
microplates in a Fourier transform infrared spectroscopy spectrometer Nicolet iS10 from 
Thermo Scientific with Smart OMNI-Transmisson accessory (Software OMNIC 8.3) (cm-1). 
NMR spectra were performed in University of Aveiro, Department of Chemistry, and were 
taken in CDCl3 (Deutero GmbH) at room temperature (r.t.) on Bruker Avance 300 
spectrometer (300.13 MHz for 1H an 75.47 for 13C). 13C NMR assignments were made by 
2D (HSQC and HMBC) NMR experiments (long-range 13C-1H coupling constants were 
optimized to 7 Hz). 
Analytical HPLC-DAD (High-performance liquid chromatography-diode array 
detector) analyses were performed on a SpectraSYSTEM (Thermo Fisher Scientific, Inc, 
USA) equipped with a P4000 pump, a AS3000 autosampler and a diode array detector 
UV8000. The separation was carried out on a 250 x 4.6 mm i.d. FortisBIO C18 (5 µm) 
(FortisTM Technologies Ltd, Cheshire, UK). ChromQuest 5.0 (version 3.2.1) software 
(Thermo Fisher Scientific Inc.) managed chromatographic data. Methanol (HPLC grade) 
was obtained from Carlo Erba Reagents, (Val de Reuil, Italy), acetic acid (HPLC grade) 
was obtained from Romil Pure Chemistry (Cambridge, UK) and HPLC grade water 
(Simplicity® UV Ultrapure Water System, Millipore Corporation, USA). Prior to use, mobile 
phase solvents were degassed in an ultrasonic bath for 15 min. All samples were 
dissolved and filtered through a PTFE syringe filter of 0.2µm pore size and 4 mm diameter 
90 
 
(Thermo Fisher Scientific) before injection. To determine the purity of compounds 117, 
119, 120, and 121, LC analysis was performed by isocratic elution using a mixture of 
MeOH:H2O:acetic acid (50:50:1), for compound 125 a mixture of MeOH:H2O:TEA 
(50:50:1) as mobile phase, and for compound 33 a mixture of MeOH:H2O:TEA (70:30:1) 
as mobile phase. The flow rate was set at 1 mL/ min. The injected volume was 10 µL and 
the eluent was monitored at 254 nm for every compound except compound 33 which was 
monitored at 399nm. The final concentration of the tested compounds was 100 µg/mL. 
The detector was set at a wavelength range of 220–500 nm with a spectral resolution of 1 
nm. The purity parameters included a 95% active peak region and a scan threshold of 5 
mAU. With these general conditions compounds 122 and 124 could not be detected (with 
different mobile phases, with and without ionic suppressors).  
UV-Vis spectra were measured in a Cary IE UV-Visible spectrophotometer 
(Varian®) with a Cary Dual cell peltier accessory (Varian®), acquiring a spectrum in a 
range of 200-800nm. Software: Cary win UV, Cary 100, version 3.00 (182). 
Qualitative GC-MS analyses were performed by Dr. Sara Cravo, Department of 
Chemistry, Laboratory of Organic and Pharmaceutical Chemistry, Faculty of Pharmacy, 
University of Porto. The analyses were performed on a Trace GC 2000 Series 
ThermoQuest gas chromatography equipped with ion-trap GCQ Plus ThermoQuest 
Finnigan mass detector. Chromatographic separation was achieved using a capillary 
columm (30m × 0.25 mm × 0.25 µm, cross-linked 5% diphenyl and 95% dimethyl 
polysiloxane) from Thermo Scientific™ and high-purity helium C-60 as carrier gas. An 
initial temperature of 80ºC was maintained for 1 min, increased to 310ºC at 10ºC/min, and 
held for 5 min giving a total run time of 33 min. The flow of the carrier gas was maintained 
at 1.5 mL/min. The injector port was set at 280ºC. Analyses were performed with splitless 
injection in the full-scan mode in the scan range of m/z 50-700. For derivatized samples 
30 µL of MSTFA were added and samples heated at 80ºC for 30 min to accomplish 
silylation. An aliquot of 1 µL of the derivatized extract was injected into the GC-MS 
system. HRMS results were obtained in the services of C.A.C.T.I. (Vigo, Spain). 
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2. Synthesis 
 
2.1. Synthesis of 4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one 
(117) 
The reagents vanillin (10.03 g, 65.89 mmol) and acetone (3 mL, 40.6 mmol) were 
dissolved in EtOH (100mL). This mixture was allowed to stir for 5 min and cooled to 0oC 
(ice bath) before the drop wise addition of 70 mL of a 40% KOH aqueous solution. The 
mixture was stirred for approximately 24 h at r.t.. The reaction was neutralized by adding a 
10% aqueous solution of hydrochloric acid and the precipitate formed was filtrated. The 
crude product was purified by recrystallization from EtOH, furnishing an yellow solid of 4-
(4-hydroxy-3-methoxyphenyl)but-3-en-2-one (117, 3.13g, 64%). 
 
4-(4-Hydroxy-3-methoxyphenyl)but-3-en-2-one (117): mp 127-129oC (EtOH) (lit. 
127-128 oC n-hexane: EtOAc 105). Purity: 96%. IR (KBr) υmax cm
-1 3200-500, 3002, 1637, 
1583, 1519,, 1452, 1297, 1267, 1226, 1188, 1124, 1026, 981. UV maximum absorption 
wavelengths 399, 243, 222, and 205 nm, with respective ε of 11400, 5700, 4900, and 
6000 M-1·cm-1. 1H NMR (CDCl3, 300 MHz) δ: 7.45 (1H, d, J= 16.2 Hz, H-3), 7.09 (1H, dd, 
J= 8.1 and 1.9, H-6’), 7.05 (1H, d, J= 1.9, H-2’), 6.93 (1H, d, J= 8.1 Hz, H-5’), 6.59 (1H, d, 
J= 16.2 Hz, H-2), 6.00 (1H, s, H-4’), 3.92 (3H, s, H-3’), 2.37 (3H, s, H-1’’); 13C NMR (75.47 
MHz, CDCl3) δ: 198.7 (C-1), 148.4 (C-4’), 147.0 (C-3’), 144.0 (C-3), 126.8 (C-1’), 124.9 
(C-2), 123.6 (C-6’), 114.9 (C-5’), 109.4 (C-2’), 56.0 (C-3’’), 27.3 (C-1’’). EI-MS (70 eV) m/z 
(rel. intensity, %): 264 (M+, 96), 265 (M+1, 30), 233 (100), 219 (52), 191 (26), 102 (20). 
 
 
2.2. Synthesis of 1,5-bis(4-hydroxy-3-methoxyphenyl)penta-1,4-dien-
3-one (33) 
The reagents vanillin (10.015 g, 6.67 mmol) and N-methyl-piperidone (4.5 mL, 37 
mmol) were dissolved in EtOH (48 mL). This mixture was allowed to stir for 5 min and 
cooled to 0oC (ice bath) before the drop wise addition of 28 mL of a 20% NaOH aqueous 
solution. The mixture was stirred for approximately 24 h at room temperature, then 100 
mL of distilled H2O was added, and the resulting orange-brown solution was neutralized 
by adding a 10% aqueous solution of hydrochloric acid. After solvent evaporation, the 
crude product acidified with 20% aqueous solution of hydrochloric acid and extracted with 
CHCl3 (3×100 mL). The organic phase was dried by anhydrous sodium sulfate, filtrated 
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and concentrated under reduced pressure to furnish a brown oil. The brown oil was 
dissolved in MeOH and basified with 20% methanolic solution of NH3. Then, the solution 
was applied in a Discovery® DSC-SAX SPE anionic exchange cartridge. The first yellow 
fraction, showed a new yellow spot on TLC plates. This fraction was concentrated and 
purified by flash chromatography (SiO2; n-hexane: EtOAc several proportions). The 
fractions that eluted with n-hexane: ethyl acetate 8:2 were gathered and concentrated 
affording an orange-brown oil of 1,5-bis(4-hydroxy-3-methoxyphenyl)penta-1,4-dien-3-one 
(33, 57.1 mg, 5%). 
 
3,5-bis(4-Hydroxy-3-methoxybenzylidene)-1-methylpiperidin-4-one (33): 74-79oC (n-
hexane:EtOAc) (lit. mp 68-70oC, MeOH 106). Purity 72%. IR (KBr) υmax cm
-1 3200-3500, 
2934, 1639, 1587, 1511, 1449, 1267, 1159, 1104, 1029, 981, 852, 811. UV maximum 
absorption wavelengths 387, 368, 264 and 208 nm, with respective ε of 11100, 10000, 
6000, and 12800 M-1·cm-1. 1H NMR (CDCl3, 300 MHz) δ: 7.68 (2H, d, J= 15.5 Hz, H-3), 
7.18 (2H, dd, J= 8.2 and 1.8 Hz, H-6’), 7.11 (2H, d, J= 1.8 Hz, H-2’), 6.92 (2H, d, J= 8.2 
Hz, H-5’), 6.94 (2H, d, J= 15.5 Hz), 5.99 (2H, brs, H-4’), 3.95 (6H, s, H-3’); 13C NMR 
(75.47 MHz, CDCl3) δ: 188.9 (C-1), 148.2 (C-4’), 147.2 (C-3’), 143.3 (C-3), 127.5 (C-1’), 
123.4 (C-2), 123.3 (C-6’), 114.9 (C-5’), 109.8 (C-2’), 56.0 (C-3’’). HRMS- Electrospray 
ionization (ESI) (+) m/z: Anal. Calc. for C19H19O5 [M-H]
+ 327.12; found: 327.12265. 
 
2.3. Synthesis of 4-(4-(allyloxy)-3-methoxyphenyl)but-3-en-2-one 
(119) 
To a solution of 4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one (117) (102.9 mg, 
0.315 mmol) and allyl bromide (60 µL, 0.693 mmol) in acetone (20 mL), Cs2CO3 (121.2 
mg, 0.37 mmol) was added and placed in a opened microwave reactor. The mixture under 
stirring was irradiated at 200 W for 2h, at a final temperature of 65oC. The solid was then 
removed by filtration with a sintered glass Buchner funnel under reduced pressure. The 
yellow-orange solution was evaporated and the product purified by semi-flash 
chromatography (SiO2; petroleum ether: diethyl ether: several proportions). The fractions 
that eluted with petroleum ether: diethyl ether 8:2 were gathered and concentrated 
furnishing a yellow solid of 4-(4-(allyloxy)-3-methoxyphenyl)but-3-en-2-one (119, 70 mg, 
56%). 
 
4-(4-(Allyloxy)-3-methoxyphenyl)but-3-en-2-one (119): mp 52-55oC (petroleum 
ether: diethyl ether). Purity 98%. IR (KBr) υmax cm
-1 2960, 2924, 1664, 1639, 1624, 1593, 
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1511, 1418, 1362, 1252, 1164, 1134, 997, 969, 800. 1H NMR (CDCl3, 300 MHz) δ: 7.46 
(1H, d, J= 16.2 Hz, H-3), 7.11 (1H, d, J= 2.0 Hz, H-6’), 7.08 (1H, s, H-2’), 6.88 (1H, d, J= 
8.1 Hz, H-5’), 6.61 (1H, d, J= 16.2 Hz, H-2), 6.15-6.02 (1H, m, H-8’), 5.46-5.39 (1H, m, H-
9’), 5.35-5.30 (1H, m, H-10’), 4.67-4.65 (2H, dt, J= 5.4 and 1.4 Hz, H-7’), 3.92 (3H, s, H-
3’), 2.38 (3H, s, H-1’’); 13C NMR (75.47 MHz, CDCl3) δ: 198.4 (C-1), 150.3 (C-4’), 149.6 
(C-3’), 143.6 (C-3), 132.7 (C-8’), 127.5 (C-1’), 125.3 (C-2), 122.8 (C-6’), 118.5 (C-9’), 
112.8 (C-5’), 110.0 (C-2’), 69.7 (C-7’), 55.9 (C-3’’), 27.4 (C-1’’). EI-MS (70 eV) m/z (rel. 
Intensity, %): 233 (M+1, 18), 232 (M+, 100), 191 (95), 163 (28), 135 (22). 
 
2.4. Synthesis of 4-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)but-3-en-
2-one (120) 
4-(4-Hydroxy-3-methoxyphenyl)but-3-en-2-one (117) (1.00 g, 3.07 mmol) and 
propargyl bromide (1 mL, 11.22 mmol) were dissolved in acetone (180 mL), Cs2CO3 
(680.03 mg, 2.08 mmol)  was added and placed in an open vessel microwave reactor. 
The mixture under stirring was irradiated at 200 W for 1h 30 min, at a final temperature of 
65oC. The solid was then removed by filtration with a sintered glass Buchner funnel under 
reduced pressure. The yellow solution was concentrated and the product submitted to a 
semi-flash chromatography (SiO2; petroleum ether: diethyl ether: several proportions). The 
fractions that eluted with petroleum ether: diethyl ether 8:2 were gathered and after 
solvent evaporation a recrystallization from diethyl ether: petroleum ether (4:1) was 
performed providing a white solid of 4-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)but-3-en-2-
one (120, 101 mg, 8%). 
 
4-(3-Methoxy-4-(prop-2-yn-1-yloxy)phenyl)but-3-en-2-one one (120): mp 110-111oC 
(diethyl ether: petroleum ether). Purity 96%. IR (KBr) υmax cm
-1 3258, 2922, 2851, 1673, 
1597, 1515, 1424, 1372, 1272, 1247, 1225, 1168, 1145, 1034, 1006, 984, 805, 723,682. 
1H NMR (CDCl3, 300 MHz) δ: 7.46 (1H, d, J= 16.2 Hz, H-3), 7.13 (1H, d, J= 8.2 Hz, H-6’), 
7.09 (1H, s, H-2’), 7.04 (1H, d, J= 8.2 Hz, H-5’), 6.62 (1H, d, J= 16.2 Hz, H-2), 4.81 (2H, s, 
H-7’), 3.91 (3H, s, H-3’’), 2.53 (1H, s, H-9’), 2.37 (3H, s, H-1’’); 13C NMR (75.47 MHz, 
CDCl3) δ: 198.4 (C-1), 149.8 (C-4’), 149.0 (C-3’), 143.3 (C-3), 128.5 (C-1’)125.7 (C-2), 
122.5 (C-6’), 113.6 (C-5’), 110.2 (C-2’), 77.9 (C-8’), 76.3 (C-9’), 56.6 (C-7’), 55.9 (C-3’’), 
27.4 (C-1’’). EI-MS (70 eV) m/z (rel. intensity, %): 231 (M+1, 25), 230 (M+, 88), 191 (100), 
163 (22). 
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2.5. Synthesis of (2R,4S,5R)-5-acetamido-2-(acetoxymethyl)-6-(2-(4-
((2-methoxy-4-((E)-3-oxobut-1-en-1-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-
yl)ethoxy)tetrahydro-2H-pyran-3,4-diyl diacetate (121) 
A mixture of 4-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)but-3-en-2-one (120) (60.0 
mg, 0.149 mmol), 2-azidoethyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-
galactopyranoside (123.6 mg, 0.297 mmol) CuSO4.5H2O (80.1 mg, 0.32 mmol), sodium 
ascorbate (131.1 mg, 0.66 mmol) and tetrahydrofuran/ H2O solvent mixture (2:1; 7mL), 
were placed in a opened microwave reactor. The non-homogeneous mixture under stirring 
was irradiated at 200 W for 10 min, at a final temperature of 70oC.  After filtration, THF 
was evaporated under reduced pressure and the aqueous solution was extracted with 
CHCl3 (3 x 100 mL). The organic phase was dried with anhydrous sodium sulfate, filtrated 
and concentrated under reduced pressure to furnish a light-brown solid of (2R,4S,5R)-5-
acetamido-2-(acetoxymethyl)-6-(2-(4-((2-methoxy-4-((E)-3-oxobut-1-en-1-
yl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)tetrahydro-2H-pyran-3,4-diyl diacetate 
(121, 63.4 mg, 38%). 
 
(2R,4S,5R)-5-Acetamido-2-(acetoxymethyl)-6-(2-(4-((2-methoxy-4-((E)-3-oxobut-1-
en-1-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)tetrahydro-2H-pyran-3,4-diyl 
diacetate (121): mp 84-86oC (CHCl3). Purity 97%. IR (KBr) υmax cm
-1  1748, 1667, 1596, 
1513, 1424, 1371, 1165, 1140, 1251, 1083, 1047. 1H NMR (CDCl3, 300 MHz) δ: 7.83 (1H, 
s, H-3’’’), 7.45 (1H, d, J= 16.2 Hz, H-3), 7.12-7.08 (3H, m, H-6’, H-2’ and H-5’), 6.61 (1H, 
d, J= 16.2 Hz, H-2), 5.54 (1H, d, J= 8.8 Hz, H-11’’’), 5.32 (2H, dd, J= 13.1 Hz, H-5’’’), 5.30 
(1H, s, H-1’’’), 5.15 (1H, dd, J= 13.1 and 3.2 Hz, H-4’’’), 4.65-4.55 (3H, m, H-6’’’, H-7’’’, 
and H-8’’’), 4.30-4.25 (1H, m, H-9’’’), 4.13 (1H, d, J= 1.68 Hz, H-17’’’a), 4.07-4.00 (1H, d, 
H-17’’’b), 4.07-4.00 (1H, m, H-10’’’), 3.89 (3H, s, H-3’’), 2.37 (3H, s, H-1’’), 2.15, 2.04, 1.99 
(3H, s, H-14’’’, H-16’’’, H-19’’’), 1.85 (3H, s, H-12’’’); 13C NMR (75.47 MHz, CDCl3) δ: 198.2 
(C-1), 170.7 (C-11’’’), 170.4 (C-13’’’ and C-15’’’), 170.1 (C-18’’’), 149.9 (C-4’), 149.6 (C-3’), 
143.2 (C-3), 143.2 (C-2’’’), 128.2 (C-1’), 125.7 (C-2), 125.7 (C-3’’’), 122.9 (C-6’), 113.6 (C-
5’), 110.3 (C-2’), 101.0 (C-6’’’), 70.9 (C-10’’’), 69.8 (C-8’’’), 67.4 (C-5’’’), 66.1 (C-9’’’), 62.8 
(C-1’’’), 61.4 (C-17’’’), 55.9 (C-3’’), 51.2 (C-7’’’), 50.2 (C-4’’’), 27.4 (C-1’’), 23.2 (C-12’’’), 
20.7 (C-16’’’ and C-14’’’), 20.6 (C-19’’’). 
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2.6. Synthesis of 4-(4-(2-(diethylamino)ethoxy)-3-
methoxyphenyl)but-3-en-2-one (122) 
To a solution of 4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one (117) (106.1 mg, 
0.325 mmol ) and 2-bromo-N,N-diethylethan-1-amine (175.1 mg, 0.972 mmol) in acetone 
(20 mL), K2CO3 (174.7 mg, 1.26 mmol) was added and placed in a opened microwave 
reactor. The mixture under stirring was irradiated at 200 W for 3h, at a final temperature of 
65oC. When the reaction was finished, the solid was removed by filtration with a sintered 
glass Buchner funnel under reduced pressure. After removal of acetone under reduced 
pressure the crude product was dissolved in dichloromethane, acidified with an aqueous 
solution of HCl 5N and extracted with H2O. The aqueous phase was basified with a 20% 
NaOH aqueous solution and extracted with CH2Cl2 (3×100 mL). The organic phase was 
dried with anhydrous sodium sulfate, filtrated, and concentrated under reduced pressure 
to furnish a yellow solid of 4-(4-(2-(diethylamino)ethoxy)-3-methoxyphenyl)but-3-en-2-one 
(122, 5.0 mg, 3%). 
 
4-(4-(2-(Diethylamino)ethoxy)-3-methoxyphenyl)but-3-en-2-one (122): mp 207-209 
oC (CH2Cl2). IR (KBr) υmax cm
-1 2959, 2925, 2855, 1729, 1629, 1425, 1384, 1273, 1124, 
669 . 1H NMR (CDCl3, 300 MHz) δ: 7.46 (1H, d, J= 16.2 Hz, H-3), 7.11 (1H, dd, J= 8.3 and 
1.9 Hz, H-6’), 7.07 (1H, d, J= 1.9 Hz, H-2’), 6.91 (1H, d, J= 8.3 Hz, H-5’), 6.61 (1H, d, J= 
16 Hz, H-2), 4.24 (2H, t, J= 6.2 Hz, H-7’), 3.89 (3H, s, H-3’’), 3.08 (2H, t, J= 6.2 Hz, H-8’), 
2.81 (4H, q, J= 7.2 Hz, H-9’), 2.38 (3H, s, H-1’’). 1.17 (6H, t, J= 7.2 Hz, H-10’); 13C NMR 
(CDCl3, 75.47 MHz) δ: 198.4 (C-1), 150.3 (C-4’), 149.6 (C-3’), 143.5 (C-3), 127.8 (C-1’), 
125.4 (C-2), 122.9 (C-6’), 112.7 (C-5’), 110.0 (C-2’), 66.4 (C-7’), 55.9 (C-3’’), 51.2 (C-8’), 
47.7 (C-9’), 27.4 (C-1’’), 11.0 (C-10’). 
 
2.7. Synthesis of 4-(3-(((3-
(dimethylamino)propyl)(methyl)amino)methyl)-4-hydroxy-5-
methoxyphenyl)but-3-en-2-one (123) 
N,N,N’-Trimethyl-1,3-propanediamine (160 µL, 1.04 mmol) was cooled in an ice-
bath for 5min before the dropwise addition of a 37% formaldehyde solution (78 µL) and 
glacial acetic acid (1.5 mL). After 1h stirring at room temperature 4-(4-hydroxy-3-
methoxyphenyl)but-3-en-2-one (117, 200 mg, 1.04 mmol)) was added to the mixture. The 
reaction proceeded at 65oC for 7 h and then at room temperature for 48 h. At the end of 
the reaction, water (10 mL) was added, and the solution was basified with a 20% NaOH 
aqueous solution and extracted with CH2Cl2 (3×100 mL). The organic phase was dried by 
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anhydrous sodium sulfate, filtrated, and the solvent evaporated under reduced pressure. 
The solid thus obtained was purified by chromatography flash cartridge using MeOH 
(100%) and MeOH:TEA (100:1). The target compound was eluted using the later mobile 
phase. The fractions were gathered and concentrated furnishing a yellow-orange solid of 
4-(3-(((3-(dimethylamino)propyl)(methyl)amino)methyl)-4-hydroxy-5-methoxyphenyl)but-3-
en-2-one (123, 65.5 mg, 20%) 
 
4-(3-(((3-(dimethylamino)propyl)(methyl)amino)methyl)-4-hydroxy-5-
methoxyphenyl)but-3-en-2-one (123): mp 122-125oC (MeOH). IR (KBr) υmax cm
-1 3500-
3200, 2962, 1633, 1471, 1385, 1126, 619. 1H NMR (CDCl3, 300 MHz) δ: 7.48 (1H d, J= 
16.05 Hz, H-3), 7.02 (1H, d, J= 1.7 Hz, H-6’), 6.84 (1H, d, J= 1.7 Hz, H-2’), 6.60 (1H, d, J= 
16.05 Hz, H-2), 3.92 (3H, s, H-3’’), 3.75 (2H, s, H-7’), 2.92-2.81 (4H, m, H-9’ and H-11’), 
2.41 (6H, s, H12’), 2.36 (3H, s, H-1’’), 1.99 (3H, s, H-8’), 1.33-1.25 (2H, m, H-10’). 13C 
NMR (CDCl3, 75.47 MHz) δ: 198.3 (C-1), 150.6 (C-4’), 148.3 (C-3’), 143.9 (C-3), 125.1 
(C-1’), 124.3 (C-2), 123.4 (C-6’), 109.8 (C-5’), 109.7 (C-2’), 61.1 (C-7’), 57.1 (C-11’), 55.9 
(C-3’’), 55.2 (C-9’), 45.4 (C-8’ and C-12’), 27.0 (C-1’’), 24.9 (C-10’). 
 
2.8. Synthesis of tert-butyl (2-(2-methoxy-4-(3-oxobut-1-en-1-
yl)phenoxy)ethyl)carbamate (124) 
4-(4-Hydroxy-3-methoxyphenyl)but-3-en-2-one (117) (202.5 mg, 0.621 mmol), 2-
(boc-amino) and ethyl bromide (274 mg, 1.22 mmol) were dissolved in acetone (40 mL), 
K2CO3 (204.5 mg, 1.48 mmol) was added and placed in a opened microwave reactor. The 
mixture under stirring was irradiated at 200 W for 3 h, at a final temperature of 65oC. The 
solid was removed by filtration with a sintered glass Buchner funnel under reduced 
pressure. The yellow solution was purified by semi-flash chromatography (SiO2; petroleum 
ether: diethyl ether: several proportions). The fractions that eluted with petroleum ether: 
diethyl ether 7:3 were gathered and the product purified by preparative chromatography 
with CHCL3: acetone: trielthylamine (9:1:0.1) affording an yellow solid of tert-butyl (2-(2-
methoxy-4-(3-oxobut-1-en-1-yl)phenoxy)ethyl)carbamate (124, 4 mg, 1.1%). 
 
tert-Butyl (2-(2-methoxy-4-(3-oxobut-1-en-1-yl)phenoxy)ethyl)carbamate (124): mp 
89-92 oC (CHCl3: acetone). IR (KBr) υmax cm
-1 3447, 2920, 2852, 1636, 1385, 1099, 668. 
1H NMR (CDCl3, 300 MHz) δ: 7.45 (1H, d, J= 16.2 Hz, H-3), 7.10 (1H, dd, J= 8.1 and 1.8 
Hz, H-6’), 7.06 (1H, d, J= 1.8 Hz, H-2’), 6.94 (1H, d, J=8.1 Hz, H-5’), 6.59 (1H, d, J= 16.2 
Hz, H-2), 4.91 (2H, m, H-7’), 3.94 (3H, s, H-3’), 3.23-3.18 (2H, m, H-7’), 2.37 (3H, s, H-1’’), 
2.17 (9H, s, H-10’); 13C NMR (75.47 MHz, CDCl3) δ: 198.5 (C-1), 160.5 (C-9’), 148.2 (C-
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4’), 146.9 (C-3’), 143.8 (C-3), 127.0 (C-1’), 125.0 (C-2), 123.6 (C-6’), 114.8 (C-5’), 109.3 
(C-2’), 68.2 (C-7’), 56.0 (C-3’’), 29.7 (C-11’), 27.3 (C-1’’). EI-MS (70e V) m/z (rel. intensity, 
%): 335 (M+, 26), 281 (100), 234 (63), 74 (82). 
 
2.9. Synthesis of tert-butyl (3-(2-methoxy-4-(3-oxobut-1-en-1-
yl)phenoxy)propyl)carbamate (125) 
A mixture of 4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one (117) (101.6 mg, 0.311 
mmol), 3-(boc-amino) propyl bromide (137 mg, 0.575 mmol), K2CO3 (105.2 mg, 0.76 
mmol), and acetone (30 mL), was placed in an opened microwave reactor. The mixture 
under stirring was irradiated at 200 W for 3 h, at a final temperature of 65oC. The solid 
was removed by filtration with a sintered glass Buchner funnel under reduced pressure. 
The yellow solution was purified by semi-flash chromatography (SiO2; n-hexane: diethyl 
ether: several proportions). The fractions that eluted with n-hexane: diethyl ether 7.5:2.5 
were gathered and after solvent evaporation a recrystallization from diethyl ether: 
petroleum ether (4:1) was performed providing a yellow solid of tert-butyl (3-(2-methoxy-4-
(3-oxobut-1-en-1-yl)phenoxy)propyl)carbamate (125,16.6 mg, 9%). 
 
tert-Butyl (3-(2-methoxy-4-(3-oxobut-1-en-1-yl)phenoxy)propyl)carbamate (125): mp 
108-110oC (diethyl ether: petroleum ether). Purity 96%. IR (KBr) υmax cm
-1  3377, 1686, 
1669, 1644, 1621, 1595, 1518, 1273, 1260, 1225, 1167, 1138, 1033, 975. 1H NMR 
(CDCl3, 300 MHz) δ: 7.46 (1H, d, J= 16.2 Hz, H-3), 7.11 (1H, d, J= 8.2 Hz, H-6’), 7.07 (1H, 
s, H-2’), 6.86 (1H, d, J= 8.2 Hz, H-5’), 6.61 (1H, d, J= 16.2 Hz, H-2), 5.50 (1H, brs, H-10’) 
4.14 (2H, t, J= 5 Hz, H-7’), 3.92 (3H, s, H-3’’), 3.38 (2H, d, J= 5 Hz, H-9’), 2.38 (3H, s, H-
1’’), 2.04 (2H, t, J= 5 Hz, H-8’), 1.46 (9H, s, H-11’); 13C NMR (75.47 MHz, CDCl3) δ: 198.4 
(C-1), 156.1 (C-10’), 150.5 (C-4’), 149.5 (C-3’), 143.5 (C-3), 127.6 (C-1’), 125.3 (C-2), 
122.9 (C-6’), 112.2 (C-5’), 109.7 (C-2’), 79.0 (C-11’), 68.2 (C-7’), 55.8 (C-3’’), 38.9 (C-9’), 
30.9 (C-8’), 28.5 (C-12’), 27.4 (C-1’’). EI-MS (70e V) m/z (rel. Intensity, %): 349 (M+, 96), 
308 (32), 261 (38), 253 (52). 
 
2.10. Synthesis of methyl 2-(2-methoxy-4-(3-oxobut-1-en-1-
yl)phenoxy)acetate (126) 
4-(4-Hydroxy-3-methoxyphenyl)but-3-en-2-one (117) (150 mg, 0.78 mmol) and 
methyl 2-bromoacetate (80 µL; 0.78 mmol) were dissolved in acetone (20 mL) and K2CO3 
(261 mg; 1.89 mmol) was added. The mixture was placed in an opened microwave 
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reactor where it was irradiated at 200 W for 3h, at a final temperature of 65oC with stirring. 
The solid was removed by filtration with a sintered glass Buchner funnel under reduced 
pressure. After acetone evaporation, the crude product was dissolved in a basified 
aqueous solution with 20% NaOH and extracted with CH2Cl2 (3×100 mL). The organic 
phase was dried by anhydrous sodium sulfate, filtrated, and concentrated under reduced 
pressure to furnish a yellow solid of methyl 2-(2-methoxy-4-(3-oxobut-1-en-1-
yl)phenoxy)acetate (126, 7.9 mg, 4%). 
 
Methyl 2-(2-methoxy-4-(3-oxobut-1-en-1-yl)phenoxy)acetate (126): mp 79-81oC 
(CH2Cl2). IR (KBr) υmax cm
-1 2918, 2849, 1733, 1634, 1515, 1463, 1262, 1111, 668. 1H 
NMR (CDCl3, 300 MHz) δ:7.45 (1H, d, J= 16.2 Hz, H-3), 7.09 (2H, dd, J= 6.7 and 1.9 Hz, 
H-6’ and H-2’), 6.80 (1H, d, J= 6.7 Hz, H-5’), 6.61 (1H, d, J= 16.2 Hz, H-2), 4.76 (2h, s, H-
7’), 3.93 (3H, s, H-3’’), 3.81 (3H, s, H-8’), 2.38 (3H, s, H-1’’); 13C NMR (75.47 MHz, CDCl3) 
δ: 198.4 (C-1), 169. (C-8’), 149.7 (C-4’), 149.3 (C-3’), 143.2 (C-3), 128.8 (C-1’), 125.5 (C-
2), 122.5 (C-6’), 113.4 (C-5’), 110.5 (C-2’), 66.0 (C-7’), 56.0 (C-3’’), 52.4 (C-9’), 27.4 (C-
1’’). 
 
 
3. Stability and photostability studies 
 
3.1. Stability sudy 
 
Standard solutions of curcumin (1), compound 117 and 33 were prepared and 
injected in the HPLC equipment with a final concentration of 1mg/mL in DMSO, at room 
temperature and immediately after being prepared. Regarding pH stability assay, five pH 
values were selected and obtained with following buffers: HCl pH 1.0, sodium acetate pH 
5.0, potassium phosphate pH 6.7, PBS pH 7.4 and sodium boric acid pH 9.1. A stock 
solution of each compound was prepared with the initial concentration of 10-2 M in DMSO. 
Then the compounds were dissolved in each buffer in a final concentration of 10-4  M. The 
solutions were allowed to incubate overnight at room temperature, except in HCl buffer 
that incubated only for 75 min, protected from light exposure. After overnight or 75min of 
incubation certain compounds precipitated. In such cases, the precipitate was filtrated and 
dissolved in 4 mL of MeOH before being also injected.  
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 The biological buffer assay was performed with cells medium. Cells medium 
composition was: 87.5 % RPMI medium, 2.5% N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid (HEPES), and 10% fetal bovine serum (FBS).The compounds were 
incubated for 5, 10, 20, and 30 min at 37o C in biological buffer, protected from light 
exposure, at a final concentration of 1.5×10-3 M. Before being injected the samples were 
filtrated. 
Solutions at 10-4 M in DMSO of each compound were prepared and store at -20oC, 
4oC and r.t. for 6, 15 and 21 days for the temperature/storage time assay. After the 
indicated storage time, where the samples were protected from light exposure, the 
solutions were filtrated and injected. All samples were filtrated using 0.80 µm Minisort ® 
filters (Sartorius Stedim Biotech)  
3.2. Photostability study 
 
The photostability of curcumin, compound 117 and 33 was determined by UV-Vis 
spectrophotometry. Stock solutions of these three compounds were prepared in MeOH at 
a concentration of 1mg/mL (2.72×10-3M for curcumin, 5.2×10-3M for compound 117, and 
2.62×10-3M for compound 33). The compounds were then dissolved to a final 
concentration of 1×10-4M. The solutions were maintained in glass vials and irradiated with 
a 120 Watts lamp in a VILBER LourMAT chamber, with a constant temperature of 430C. 
The solutions were subjected to selected times intervals of light exposure: 30min, 1h, 2h, 
3h and 24h, and compared to 0min light exposure (standard). One solution of each 
compound was also prepared and protected from light exposure for 3h and 24h. The 
experiences were carried out in duplicate. Methanol was used to define the baseline. 
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